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The Effect of Nutrients Upon the Activity of SR Proteins 
 
Callee McConnell Walsh 
 
 RNA splicing is an important component of gene expression that contributes 
immensely to the biological complexity of higher eukaryotes.  The regulation of 
splicing by external stimuli, such as nutrients, is poorly understood, however.  The 
experiments contained herein sought to understand how the activity of splicing 
factors called SR proteins is regulated by insulin and polyunsaturated fatty acids in 
the liver using the model mRNA glucose-6-phosphate dehydrogenase (G6PD).  RNA 
affinity and chromatin immunoprecipitation experiments demonstrated that refeeding 
of rodents stimulates the binding of SR proteins to the splicing regulatory element of 
G6PD; and this was especially relevant for SRp20.  In vitro and in vivo splicing 
assays demonstrated that SRp20 is relevant for the splicing of G6PD.  Additionally, 
analysis of SR proteins in hepatocytes determined that insulin stimulates the amount 
of phosphorylated SRp20 in the nucleus by 13-fold while the polyunsaturated fatty 
acid, arachidonic acid, attenuated this by 80%.  A similar pattern was observed for 
SRp30 a/b and SRp40.  These data suggest that the increase in binding activity of 
SRp20 during refeeding is stimulated by the increase in phosphorylation via insulin.  
These findings demonstrate that the activity of SR proteins changes in response to 
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The process of gene expression involves coordination of many different processes 
within different regions of the cell.  Beginning with transcription to pre-mRNA 
processing to finally translation, the many processes are complex, intertwined, and 
elegantly coordinated.  The discovery of split genes occurred in 1977 (1), revealing the 
importance of splicing, the process of intron removal and exon ligation, in gene 
expression.  Most markedly, since the sequence of the human genome was completed in 
2003, it is realized that splicing expands the protein diversity gleaned from our relatively 
small number of genes, and recent reports indicate that greater than 90% of our genes 
undergo alternative splicing (2, 3).  Regulation of splicing is, thus far, a poorly 
understood area of research that is just beginning to be explored.  As numerous recent 
reports indicate that splicing is interconnected to other aspects of gene processing and 
expression, it is becoming increasingly important to understand the regulatory processes 




 The process of transcription in eukaryotes is complex and is regulated at many 
stages.  General transcription factors assist RNA polymerase II (Pol II) to bind to 
promoters and initiate transcription at the transcription start site, which is demarcated by 
the initiator motif, YYANWYY, in humans (W=T/A) (4, 5).  The core promoter 
recognition motif is the TATA box, 25-33 base pairs upstream of the start site, which is 
recognized by the general transcription factor TBP (TATA-box binding protein), a 
component of TFIID (5).  Upon the binding of TBP to the TATA box, TFIIB binds 
followed by TFIIF, Pol II, TFIIE, and TFIIH, which completes the formation of the 
preinitation complex (5).  TFIIH has helicase activity to unwind the DNA strands at the 
transcription start site and allows transcription to proceed.  This protein also 
phosphorylates the C-terminal domain (CTD) of Pol II to allow transcriptional elongation 
to begin. Many other factors regulate the transcription process beyond these general 
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transcription factors, however.  Transcription factor binding sites and the transcription 
factors that bind to them regulate the recruitment of Pol II to promoters and transcription 
start sites.  Also, transcriptional repressor sequences and repressor proteins can inhibit 
this process in response to appropriate stimuli.  Transcription factor binding sites are 
often located long distances upstream or downstream from the promoters they regulate 
(6).  Additional regulatory control of transcription is provided by histones to which 
chromatin is bound.  Specific combinations of acetylation and methylation of residues 
within histones 3 and 4 are associated with euchromatin, which allows greater access of 
Pol II to promoters.  Other discrete combinations of mainly methylated and some 
acetylated residues are associated with transcriptionally inactive heterochromatin (7).  
Pol II is a multimeric enzyme that is unique among other RNA polymerases in the 
cell.  Each polymerase transcribes different classes of RNAs with Pol II transcribing 
mRNAs and most of the small nuclear RNAs that are components of small nuclear 
ribonucleoproteins (snRNPs) involved in splicing.  Pol I transcribes rRNAs, and Pol III 
transcribes mainly tRNAs.  Of the three RNA polymerases, only Pol II contains the 
unique domain, the CTD.  In mammals, this domain consists of 52 repeats of the 
sequence YSPTSPS of which 21 of these repeats diverge to some extent from the 
consensus.  Although 5 of the 7 residues within the repeat are subject to phosphorylation, 
the serines located at position 2 and 5 are the main targets of regulation.  Serine 5 is 
associated with transcription initiation and promoter clearance and serine 2 
phosphorylation is important for elongation of transcription (8, 9).  Several of the mRNA 
processing factors, such as the enzymes involved in 5’ cap and poly (A) tail formation, 
are directly recruited to the CTD of Pol II (10), which allows for co-transcriptional 
processing as soon as the nascent pre-mRNA emerges from the enzyme.  Therefore, the 
unique CTD of Pol II is responsible for initiating the 5’ cap and poly (A) tail 
(polyadenylated tail) upon mRNAs, which distinguishes them from other cellular RNAs.   
 
Pre-mRNA processing, export, and translation 
 
 As the pre-mRNA is being described, it is modified through several processing 
steps.  These include 5’ capping, removal of introns in splicing, and cleavage and 
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addition of the poly(A) tail to the 3’ end of the pre-mRNA.  These processing steps 
increase the stability of the mRNA, properly order the sequences of exons in the mRNA, 
and increase its ability to be exported from the nucleus to the cytoplasm for translation.  
The first step in pre-mRNA processing is capping of the 5’ end of the pre-mRNA 
after 25-30 nucleotides have emerged from Pol II.  Three enzymatic activities are 
necessary including a tri-phosphatase, a guanyl transferase, and a methyl transferase, 
which are associated with the CTD.  Their activity converts the pppA 5’ terminus to a 7-
methyl guanosine cap (11).  The cap is necessary for stability, splicing, polyadenylation, 
export, quality control, and translation of the mature mRNA (12).  The cap recruits the 
cap binding protein, which is a heterodimer consisting of CBP-80 and CBP-20.  These 
binding proteins initiate cap-dependent translation early in the translation process and are 
important for the pioneer round of translation, being subsequently replaced by translation 
factors during steady state translation (13).  
The next processing activity upon the pre-mRNA is removal of intronic sequences 
from the protein-coding exonic sequences, which is termed mRNA splicing. Although the 
two transesterification reactions required for splicing are catalyzed completely by the 
RNA itself, several ribonucleoprotein complexes are necessary for the structural 
organization of the pre-mRNA to achieve a catalytically active intron.  Sequences within 
the introns and exons of RNA provide docking sites for many of the ribonucleoproteins 
and proteins involved in the splicing process.  The most basic sequence requirements for 
splicing are found within introns, which include the 5’ splice site (GU), the branch point 
(A), the polypyrimidine tract, and the 3’ splice site, AG (Figure 1; 14).  These sequences 
recruit snRNPs and other accessory proteins to the intron to form the protein complex 
called the spliceosome.  Specifically, U2AF65 binds to the polypyrimidine tract, U2AF35 
binds to the 3’ splice site, SF1 binds to the branch point, and U1 snRNP binds to the 5’ 
splice site through direct RNA-RNA and protein-RNA interactions.  This initial assembly 
of proteins constitutes the E complex or early complex of the spliceosome.  Following 
formation of the E complex, U2 snRNP interacts with the branch point A in an ATP-
dependent manner and forms the A complex of proteins.  The B complex is formed next 
by the addition of the tri-snRNP containing U4/5/6 snRNPs.  This complex of proteins 
rearranges the RNA in order for the first transesterification reaction to occur via 
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nucleophillic attack of the 5’ splice site by the branch point A.  Next, the 5’ splice site 
attacks the 3’ splice site resulting in formation of the intron as a free lariat and the 
splicing together of adjacent exons.  This is an overly simplified description of the 
splicing process because the spliceosome is estimated to contain over 100 proteins (15), 
and the activity as well as the coordination of all of the proteins  
 
within the spliceosome is poorly understood.  Among the components of this complex, 
the activity of a few protein families is emerging.  Helicases are an important component 
of the spliceosome for their function in rearranging protein-protein and protein-RNA 
complexes, allowing dynamic changes in the spliceosome.  The main family members 




Figure 1.  The Complexes of the Spliceosome.  SnRNPs and accessory factors bind 
to the consensus sequences within the intron to form the initial complexes of the 
spliceosome.  5’ splice site = GU, 3’ splice site = AG, branch point = A, 




proteins (serine-arginine rich proteins) and hnRNPs (heterogeneous ribonucleoproteins) 
are important mediators of the splicing process with regulation of spliceosome formation 
being their best-characterized function.  Proper removal of intervening introns 
consequently deposits a complex of proteins 20-24 nucleotides upstream of the exon-
exon junction, which is called the exon junction complex (17, 18).  The exon junction 
complex is important for quality control processes and export of the mRNA.   
Polyadenylation is the final processing step upon the mRNA.  The sequence of 
most mRNAs contains a polyadenylation signal (AAUAAA) and a downstream element 
consists of either a G/U or a U-rich sequence (19).  Both are located within the 3’ 
untranslated region.  The cleavage and polyadenylation specificity factor first binds to the 
5’ poly(A) signal, which then recruits the cleavage stimulatory factor, cleavage factor I, 
cleavage factor II, and finally poly(A) polymerase (19).  Upon formation of this protein 
complex, the mRNA is cleaved between the poly(A) signal and downstream element and 
poly(A) polymerase proceeds to add 200-250 A residues (19).  Poly(A) binding proteins 
then bind to the poly(A) tail, which stabilize the mRNA through interaction with the cap-
binding complex, inhibiting the access of RNases.  Additionally, alternative 
polyadenylation sites exist and are a common mechanism to enhance protein diversity 
(20). 
RNA export into the cytoplasm depends upon the sequential deposition of several 
proteins during capping, splicing, and polyadenylation processes.  Both the 5’ cap and the 
exon junction complexes, placed upon the mRNA during splicing, are necessary for 
recruitment of the transcription export factor called TREX and its component ALY (21-
23).  The poly(A) tail recruits nucleoporin proteins that are components of the nuclear 
pore complex (24).  Components of TREX interact with TAP and several other proteins, 
which bind the mRNA to the export receptor (25).  The export receptor interacts with 
phenylalanine and glycine rich domains within the nuclear pore complex, and the mRNA 
is exported via facilitated diffusion (26).  After a series of successive removals of 
proteins performed by DEAD-box proteins, the cap binding protein is replaced by the 
translation initiation factor, eIF4E.     
Translation of the mRNA is an extremely complex process with many proteins 
involved.  As this review focuses upon mRNA processing and, specifically, splicing, 
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translation will only be described in general as is sufficient to place it in the context of 
the impact of splicing factors upon the translation process.  Translation is initiated with 
the binding of the preinitiation complex. This complex scans the 5’UTR of the mRNA to 
identify the AUG codon (25).  Translation ensues as the mRNA is held in a circular 
formation by a linkage between the 5’ cap and poly(A) tail.  Peptide bond formation 
initiates at this point with amino acids being delivered via tRNA and continues until the 
stop codon is met (27, 28).  At this point, release factors recognize the stop codon and 
promote cleavage of the peptidyl-tRNA through GTP hydrolysis, and this releases the 
new protein.  A single mRNA can be translated simultaneously by several ribosomes at 
once, but after a period of time, the mRNA integrity is undermined by deadenylases and 
de-capping enzymes, making the mRNA susceptible to nucleases.  This ceases the 
translation process.   
 
RNA Quality Control 
 
At several points during mRNA processing, quality control mechanisms remove 
improperly processed mRNAs.  The nuclear surveillance pathway removes aberrant 
transcripts through degradation in the nuclear exosome.  This pathway detects and 
degrades unspliced mRNAs, transcripts with aberrant poly(A) tails, and transcripts that 
fail to acquire the proper RNA-binding proteins throughout transcription and splicing (29, 
30).  It also eliminates the intronic lariats that arise from the splicing process after they 
are first processed by the debranching enzyme.  
Another type of surveillance pathway is nonsense-mediated decay (NMD), which 
detects the presence of premature termination codons in spliced transcripts.  Premature 
termination codons can arise through several means including errors in transcription, 
frame shift mutations, programmed DNA rearrangements, which is common in T-cell 
receptors, and also aberrant splicing (31).  Transcripts containing premature termination 
codons, if translated, could be extremely deleterious to the cell, creating truncated 
proteins with toxic gain-of or loss-of function characteristics; therefore, rapid removal of 
such transcripts is essential.  The exon junction complex is instrumental in the NMD 
pathway because it marks exon-exon junctions and also contains protein components of 
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the NMD pathway (Upf2 and Upf3).  Upon export of a transcript from the nucleus, a 
pioneering round of translation is performed that identifies premature termination codons 
located 50 nucleotides upstream of the last exon junction complex (32).  This triggers the 
NMD pathway to activate via the interaction of Upf1 with Upf2 and Upf3 (32).  The 
mRNA is degraded from the 5’ end by the Xrn1 exonuclealytic activity after decapping 
or the 3’ end by the cytoplasmic exosome after deadenylation (33, 34).  
 
Importance of Splicing 
 
There are two types of pre-mRNA splicing: constitutive splicing and alternative 
splicing.  Constitutive splicing is the removal of intervening introns and subsequent 
ligation of exons that are always present within a particular transcript and not subject to 
regulated inclusion.  Alternative splicing is the process by which exons and introns are 
included in the transcript in a regulated manner.  The types of alternative splicing are 
exon skipping, mutually exclusive inclusion of exons, alternative 5’ splice sites, 
alternative 3’ splice sites, and intron retention (Figure 2; 14). Alternative and constitutive 
splicing use the same mechanisms of splicing; the only difference is that alternative 
splicing is subject to greater regulatory variability (35).   
Alternative splicing increases the number of proteins that arise from the genome 
(36).  The human genome contains approximately 23,000 genes, while the size of the 
proteome is estimated to be upwards of 90,000 different proteins, which equates to a 
protein to gene ratio of four to one (37).  The almost unlimited combination of sequences 
that alternative splicing produces has expanded the proteome to, thus far, an 
immeasurable level in humans. These data highlight just how prevalent and how 
important alternative splicing is in human gene expression, creating multiple mRNAs and 
proteins from a single gene (36).  In fact, recent research suggests that greater than 90% 
of our genes are alternatively spliced (2, 3).  This percentage stands in stark contrast to 
the protein to gene ratio in the fly and worm where alternative splicing is less prevalent 






















Alternative splicing also enhances the diversity of proteins in the human  
proteome.  Changes in the primary sequence through alternative splicing have  
consequences for the function of the resulting protein.  Alternative splicing can change 
the binding properties, the post-translational modifications, the catalytic activity, 
localization, and many more properties of the translated proteins (38).  Alternative 
splicing also can regulate the amount of the protein that is expressed through inclusion of 
exons or introns containing premature termination codons, and this subjects the mRNA to 
NMD. The exquisite control of protein activity through alternative splicing is important 
to many processes such as development and response to external stimuli to maintain 
homeostasis.    
The process of alternative splicing is the result of several factors, which is termed 
combinatorial control.  Many factors affect exon recognition and formation of the 
spliceosome.  These factors include sequences within exons and introns, the length of 
introns and exons, the speed of transcription, the relative amounts of positive and 
negative trans factors within a certain cell type, the activity of these trans factors, and the 
position of nucleosomes with respect to splice sites.  In addition, secondary structure of 
the RNA may also exert regulatory control upon the splicing process (39). Thus, many 
levels of complexity exist in the processes of constitutive and alternative splicing, and 
many of these topics will be addressed in the following sections. 
 
Splicing Regulatory Sequences 
 
Sequences within the pre-mRNA provide binding sites for splicing factors, which 
provide regulatory control over splicing.  As discussed above, consensus sequences 
within the intron serve as binding sites for snRNPs.  Many additional sequences within 
exons and introns are also necessary for proper recognition of exons in constitutive 
splicing and regulated inclusion of exons and introns in alternative splicing.  Exonic 
splicing silencers (ESSs) are located within exons and generally inhibit the splicing 
process.  Exonic splicing enhancers (ESEs) are sequences within exons that promote 
splicing and exon recognition.  ESEs perform this task by providing binding sites for a 
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family of proteins called SR proteins. The canonical family of SR proteins includes 9G8, 
SRp20, SC35, ASF/SF2, SRp40, SRp55, SRp75, and Tra2β.  Some ESEs show 
specificity in the binding of a particular SR protein.  For example, the ESE within exon 3 
of the Tat gene promotes association of the SR protein ASF/SF2 but not SC35 (40).  On 
the other hand, some ESEs have less specificity with respect to SR protein binding such 
as in the case of ß-globin in which both SF2/ASF and SC35 can enhance splicing (40).   
ESEs and SR proteins promote inclusion of a particular sequence, but they serve 
slightly different purposes in constitutive and alternative splicing.  In the splicing of 
constitutive exons, ESEs and SR proteins play a role in distinguishing exons from the 
surrounding intronic sequences, a process called exon definition (41).  The binding of SR 
proteins to ESEs is essential for stimulating inclusion of alternatively spliced exons, 
which tend to have weak intronic splicing sequences such as nonconsensus 5’ and 3’ 
splice sites and polypyrimidine tracts (42).  In these cases, these splicing signals would be 
too weak to recruit U1 snRNP, U2AF35, or U2AF65 alone, and splicing would not occur 
or would be less efficient.  In support of this hypothesis, a recent study showed that a 
minigene that required ASF/SF2 for splicing could splice independently of ASF/SF2 
when its 5’ splice site was mutated to more closely resemble the consensus binding site 
for U6 snRNP (43). While, there is no relationship between splice site strength and the 
frequency of ESEs in constitutively spliced exons, the authors suggest that a relationship 
may exist such that weak splice sites may be associated with stronger rather than multiple 
ESEs (44). Additionally, alternative splice sites have fewer ESE motifs than constitutive 
splice sites (44), which presumably is the reason for their irregular inclusion.  
Efforts to identify and characterize ESEs have produced vague results.  One 
reason for the difficulty in identifying ESEs is that several SR proteins lack fidelity in 
sequence binding.  ESEs can be purine (A and G) rich, can contain the consensus 
sequence (GAR)n, or can be AC-rich (14, 45-47).  Additionally, ESEs are enriched in the 
regions of exons close to the 3’ and 5’ splice sites of intervening introns (46) where these 
sequences would have a higher propensity for the interaction of an SR protein with the 
basal splicing machinery (snRNPs).  Several groups have developed computer programs 
to predict ESEs based upon several parameters such as proximity to splice sites, strength 
of splice sites, and binding to SR proteins.  Another method to define binding sites is 
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called SELEX (selective evolution of ligands by exponential enrichment).  This is a 
purely in vitro method in which random sequences that are bound by the protein of 
interest are captured and enriched with PCR.  These analyses have provided degenerate 
hexamers or octamers that must be functionally examined to determine their actual role in 
splicing.   
The recent advent of high throughput sequencing, however, has created an 
opportunity to better define the sequences to which SR proteins bind.  The first definition 
of a global consensus-binding site for an SR protein was recently determined utilizing 
high throughput sequencing technology.  Using in vivo crosslinking followed by 
immunoprecipitation and sequencing of the bound RNA, the Cacerces group identified 
the global binding sequence of ASF/SF2 to be TGAT/AGAA, which is somewhat 
different from consensus binding sites identified with traditional methods (48).  This 
technique is superior to in vitro methods such as SELEX because the interaction of the 
RNA-binding protein and its target RNA is captured with the crosslinking step in intact 
cells as splicing is occurring.  The crosslinking step creates stable covalent bonds 
between the protein and RNA, which prevents rearrangement and loss of the interaction 
that can potentially occur with immunoprecipitation without a prior crosslinking step.  
High throughput sequencing enables the sequencing of tens of millions of bases within 
days (49).  Overall, in vivo crosslinking immunoprecipitation coupled with high 
throughput sequencing is a promising technique for defining consensus binding sites of 
RNA-binding proteins, which has historically been a difficult task.   
ESSs are involved in constitutive and alternative splicing events, but they have 
received much less attention than ESEs.  ESSs in general inhibit the inclusion of the exon 
in which they’re located and have major roles in alternative splicing of exons by 
inhibiting inclusion in a regulated manner.  By screening human genomic DNA libraries 
for splicing inhibitory sequences, Fairbrother and Chasin (50) concluded that ESSs and 
splicing inhibition may be quite common in the human genome.  They found that 1 in 3 
randomly chosen sequences from human DNA inhibited splicing, while only 1 in 27 
sequences from E. coli genomic DNA was inhibitory (50).  Several studies have 
attempted to characterize ESSs in a global manner.  Wang et al. (51) generated random 
decamers, inserted them into a splicing reporter minigene, and measured the resulting 
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mRNA products after transfection.  Upon sequence comparison, they identified 7 clusters 
of ESSs that contained 6 nucleotides each.  These hexamers consisted of mainly U (38%) 
and G (36%), which has also been found by others (52).  Others have characterized ESSs 
as having a high abundance of pyrimidines (50).  Additionally, ESS hexamers were 
identified more often in strong exons than weak exons that are constitutively spliced and 
more often in alternative exons that are skipped than constitutive exons (51).  In addition 
to the nucleotide sequence, the position of a sequence within an exon may determine its 
effect on splicing as a particular sequence can both enhance and repress depending on its 
location (53). Additional observations include a higher frequency of these inhibitory 
sequences found in pseudoexons than constitutively spliced exons (51).  Pseudoexons are 
found within introns and resemble authentic exons in that they contain 5’ and 3’ decoy 
splice sites that match consensus sequences, but they are rarely spliced (54).  Therefore, 
one role of silencer sequences is thought to be repression of pseudoexon splicing (51, 55).   
Besides ESEs and ESSs, additional sequences within the intron can impact the 
splicing process.  ISEs (intronic splicing enhancers) are located within introns and 
enhance recognition of particular sequences, and ISSs (intronic splicing silencers) block 
recognition of particular sequences.  A well-studied ISS is an inhibitory sequence that is 
associated with some polypyrimidine tracts.  Although the polypyrimdine tract provides a 
binding site for U2AF65 and promotes recognition of other intronic splice sites by U2 
snRNP, as discussed above, this sequence can also inhibit intron recognition.  This occurs 
through its recognition by polypyrimidine tract binding protein (PTB), which binds to the 
consensus motif, CUCUCU that is surrounded by pyrimidines.  PTB is an active 
repressor of weak exons that may function by competing with U2AF65 for binding to the 
intron (52).  In a specific example, this ISS and PTB affect alternative splicing of c-src 
pre-mRNA.  In this pre-mRNA, PTB binds to ISS sequences within the upstream and 
downstream introns surrounding the regulated exon called N1 (56, 57).  This binding is 
thought to “loop out” the N1 exon and result in exon skipping.  Interestingly, this exon is 
only skipped in non-neuronal tissues.  The reason for this tissue specific splicing is the 
expression of a neural version of PTB called nPTB (neuronal PTB) in the brain.  nPTB is 
deficient in binding to the upstream ISS; therefore, the exon is included in the final 
transcript (58).  
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ISE sequences and the proteins that bind to them enhance the inclusion of 
alternative exons.  One of the best examples of a regulatory ISE is UGCAUG which 
provides a binding site for FOX-1 and 2 proteins in transcripts from neural tissues, in 
particular (reviewed in 59).  This ISE is often located up to 400 nucleotides downstream 
from the regulated exon but can enhance inclusion from distances as great as 1000 base 
pairs downstream from the regulated exon (60, 61).  This ISE is necessary for inclusion 
of the N30 exon in myosin heavy chain B in neural tissue; in non-neural tissue this exon 
is skipped.  It was shown that the ISE substitutes for a suboptimal polypyrimidine tract 
within the intron downstream of the regulated exon, as strengthening the polypyrimidine 
tract abolished the need for this particular ISE (61).    
 The location of intronic regulatory elements within either the upstream or 
downstream intron has an impact upon inclusion of the intervening exon.  An example of 
this effect of intronic location upon alternative splicing is observed with the splicing 
protein called NOVA.  Recent experiments in which in vivo crosslinking, 
immunoprecipitation of NOVA protein, and sequencing of the transcripts to which 
NOVA was bound were performed and produced several interesting observations.  
Binding sites for NOVA in an intron upstream of a regulated exon (near the 3’ splice site) 
inhibited inclusion of the exon in the final transcript.  Conversely, binding sites for 
NOVA in the downstream intron, near the 5’ splice site, enhanced inclusion of the 
alternatively spliced exon in the final transcript (62).  This effect is due to competition for 
splicing factors where upstream enhancers outcompete downstream splice sites for 
splicing factors, leading to exon skipping.  Conversely, an ISE located in the downstream 
intron relieves competition for splicing factors from the upstream splice sites, leading to 
exon inclusion (reviewed in 59).  The NOVA splicing factor exemplifies the extreme 
importance of the location of intronic splicing sequences upon the final spliced product.  
 
HnRNPs in splicing regulation  
 
HnRNPs are a family of proteins with diverse roles in RNA metabolism.  These 
proteins are involved in RNA transport, transcription, polyadenylation, RNA decay, RNA 
localization, and splicing (63, 64).  HnRNP A1 is the best-characterized hnRNP with a 
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role in repression of splicing.  It can bind to ESS as well as ISS sequences.  As an 
example, hnRNP A1 binds to the ESS within HIV Tat exon 3, causing nucleation of 
several hnRNP A1 proteins, preventing recognition of the exon by SR proteins, and 
resulting in exclusion of the exon (65).   
HnRNP A1 can also inhibit inclusion of exons by binding to nearby introns.  An 
example of this exists for the hnRNP A1 pre-mRNA itself.  Through binding to ISS 
sequences in the intron and looping out of an alternative exon, this alternative exon is 
excluded (66).  These and many other examples indicate that hnRNPs inhibit the splicing 
process by blocking recognition of ESEs by SR proteins and/or by directly interfering 
with the recognition of splice sites by snRNPs. It should be noted, however, that in 
addition to their function in inhibition of splicing, some hnRNPs are known to enhance 
recognition of splice sites (e.g. 67).             
 
SR proteins and splicing mechanisms 
 
The family of SR proteins has roles in both constitutive and alternative splicing.  
SR proteins are expressed in all tissues, but the expression level varies by tissue (68, 69).  
Tissue-specific differences in expression levels of SR proteins (and hnRNPs) are thought 
to contribute to differences in splicing patterns between tissues.  Although initial in vitro 
studies indicated that SR proteins were functionally redundant, recent studies, in which 
individual SR proteins have been depleted, indicate that SR proteins are functionally 
specific (70).   
Two domains define SR proteins.  They contain an RNA recognition motif 
(RRM) at the N-terminus of which SR proteins contain one or two.  They also contain a 
serine-arginine rich domain (RS domain) at the C-terminus for which SR proteins are 
named.  The RS domain contains multiple arginine-serine dipeptides; for example the RS 
domain of ASF/SF2 contains 14 RS dipeptides plus 5 additional serines that are preceded 
by amino acids other than arginine (Figure 3).  The serines within the RS domain are 
targets of several kinases that modulate the activity of SR proteins.  The RRM is 
necessary for the SR protein to recognize and bind to its cognate RNA sequence, and it 














Figure 3.  Domains of SR proteins.  RRM = RNA recognition motif, RS = arginine-


























protein with that from another changes its RNA-binding pattern to that of the substituted 
RRM in vivo (71).  The RRM is dispensable in the splicing process, however, and is 
merely required for targeting of the SR protein to the proper region for splicing (72).  The 
RS domain is necessary for the activity of SR proteins in the splicing process.  There are 
two main models by which SR proteins enhance the splicing process, in general, 
including the recruitment model and the inhibitor model (35, 70). 
In the recruitment model, SR proteins bind to RNA sequences, which enhances 
the binding of snRNPs and encourages spliceosome formation at splice sites.  The RS 
domain is integral to the interaction of SR proteins with snRNPs.  In vitro studies with 
purified proteins indicate that the SR proteins, ASF/SF2 and SC35, bind to the 70 kDa 
protein of U1 snRNP and to U2AF35, and this interaction occurs via the RS domain (73-
75).  The interaction of ASF/SF2 and the U1 70 kDa protein also occurs in vivo (71), but 
currently debate exists concerning whether all SR proteins interact with U1 snRNP (cf. 
71, 74).  These protein-protein interactions are thought to stabilize the pre-spliceosomal 
complexes, define the 5’ and 3’ splice sites, and help recruit other members of the 
spliceosome (73, 74, 76).  Additionally, phosphorylation of the RS domain enhances the 
interaction of SR proteins with other splicing factors such as U1 snRNP (75, 77).  
The recruitment model of splicing is integral to the process of exon definition of 
constitutive exons.  In higher eukaryotes, pre-mRNAs typically contain long introns 
separated by short exons; thus for proper splicing to occur, the exons must be 
distinguished from the intronic sequences in a process called “exon definition” (41).  SR 
proteins are important for exon definition in which the binding of SR proteins to ESEs 
within exons distinguishes exons from intronic sequences.  This enables the recruitment 
of U2AF35, U2AF65, and U2 snRNP to the upstream 3’ splice site and U1 snRNP to the 
downstream 5’ splice site leading to spliceosome formation (41).  
In another version of the recruitment model, the RS domain of SR proteins binds 
directly to intronic RNA at the 5’ splice site and the branch point.  This interaction is 
thought to stabilize the charge repulsion at the RNA-RNA interactions between U1 and 
U2 snRNPs and pre-mRNA (78-80).  In contrast to the two mechanisms of recruitment 
that require RS domains, however, recent work indicates that RS-domain independent 
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splicing enhancement is possible (81); therefore, the role of the RS domain in recruitment 
of snRNPs may be specific to each splicing event and the SR protein involved.    
In the inhibitor model of splicing enhancement, SR proteins antagonize the effects 
of ESS sequences and inhibitory splicing proteins upon the splicing process.  ESS 
sequences are very common throughout the human genome; in fact, the default may be 
splicing inhibition (50).  As discussed above, hnRNPs are a family of RNA-binding 
proteins that, in general, are inhibitory to the splicing process through their binding to 
ESSs.  They inhibit splicing by preventing the binding of U1 and U2 snRNPs to intronic 
consensus sequences.  Several reports indicate that the binding of SR proteins to ESEs 
can counteract the inhibitory effects of ESSs when the two sequences are closely 
juxtaposed (65, 82, 83).  As an example of this type of interaction, the Krainer group 
determined that the binding of ASF/SF2 to an ESE within exon 3 of the Tat pre-mRNA 
blocks the binding of hnRNP A1 to this same region of the exon.  The binding of 
ASF/SF2 and prevention of hnRNP A1 binding enables exon recognition to proceed (65).  
 Although SR proteins are most known for their ability to enhance splicing, there 
are examples where SR proteins can antagonize the splicing process.  For example, 
SRp20 enhances and ASF/SF2 antagonizes exon inclusion in SRp20 pre-mRNA to 
regulate expression of SRp20 protein (84, 85).   
  
Regulation of SR protein activity 
 
 The ability of SR proteins to impact the splicing process depends on their ability 
to bind to target transcripts, which is generally termed their activity.  The activity of SR 
proteins in the splicing process is regulated by several factors.  As most SR proteins 
shuttle between the nucleoplasm, cytoplasm, and storage sites within the nucleus, one of 
the main ways that activity is regulated is by the location of the SR protein intracellularly.  
These shuttling processes and interactions with other splicing proteins are regulated by 
phosphorylation of the RS domain by the action of several different kinases and 
phosphatases.  An additional means of regulation of SR protein activity is through 
changes in expression, which can occur through transcriptional and post-transcriptional 
mechanisms.     
 18 
 
SR protein kinases 
 
The splicing activity of SR proteins is regulated by their location within the cell.  
SR proteins shuttle between three different cellular compartments.  They localize to 
nuclear regions called speckles when they are inactive in splicing, such as when 
transcription is inhibited (86).  From speckles, the SR proteins can move to the 
nucleoplasm where they interact with actively transcribed pre-mRNA (86).  They can 
then remain bound to the mRNA following splicing catalysis and can be exported with 
the mRNA to the cytosol (87); only SC35 doesn’t shuttle between the nucleus and cytosol 
(88).  They can then be imported back into the nucleus to speckles (Figure 4).  
Phosphorylation and dephosphorylation of the RS domain is the main mechanism by 
which the movement of SR proteins between the cytosol, nuclear speckle, and 
nucleoplasm is regulated.  An example of this regulation is exhibited in muscle cells in 
response to insulin treatment.  The Cooper lab recently demonstrated that Akt2, activated 
by insulin, phosphorylates and activates a kinase called Clk/Sty, which is a known SR 
protein kinase.  This kinase phosphorylates several SR proteins, which causes them to 
bind to the target pre-mRNA, PKCβII.  The binding of SR proteins causes inclusion of 
the PKCβII exon that results in the isoform of PKCβII that enhances glucose uptake (89).  
This example demonstrates how signaling pathways initiate phosphorylation events that 
enhance the activity of SR proteins upon target transcripts.  It should be noted, however, 
that this pathway by which SR proteins shuttle through cellular compartments through 
changes in phosphorylation is the combination of the work from several groups and has 
not been demonstrated in total for an individual SR protein.    
SR proteins are phosphorylated by several kinases.  SR protein kinases (SRPKs) 
are one family that consists of SRPK1 and 2, and they can be located in the cytosol and 
nucleus.  SRPK1 is the most studied family member, but little information is available 
concerning SRPK2 and SR proteins.  SRPK1 preferentially phosphorylates serines within 
serine-arginine dipeptides, which is the most common pattern within the N-terminal 
portion of the RS domain (90, 91). One of the roles of SRPK1 is to phosphorylate SR 
proteins while they are located in the cytosol.  Specifically, SRPK1 binds to a docking  
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motif within ASF/SF2 that directs its phosphorylation to ten serines within the N-terminal 
portion of the RS domain (91, 92).  These phosphorylations enable ASF/SF2 to bind to 
transportin, enter the nucleus, and localize to speckles (91).  As further evidence for the 
importance of SRPK1 in nuclear import, ASF/SF2 is unable to be transported from the 
cytosol into the nucleus in yeast lacking Sky1p, the yeast homologue of SRPK (77).  
SRPK1 can also contribute to the movement of SR proteins intra-nuclearly as SRPK1 
over-expression causes dispersal of ASF/SF2 and SC35 from nuclear speckles (93).  
Although ASF/SF2 and SC35 are the most-studied substrates for SRPK1, it can also 
phosphorylate SRp55 and U2AF65 (90); however, a rigorous test of the action of SRPK1 
upon all SR proteins is critically needed.  
One mechanism in which the nuclear activity of SRPK1 is regulated is by its 
sequestration in the cytoplasm during certain phases of cell growth and in response to 
specific signals.  In interphase cells, SRPK1 is mainly localized in the cytoplasm, but 




Figure 4.  Shuttling of SR Proteins.  SR proteins shuttle between different cellular 
compartments in response to kinase and phosphatase activity.  Transp SR=transportin 
SR, TAP= TAP exporter, PP= phosphatase.  Adapted from Ngo et al., 2005.   
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which the majority of SRPK1 moves into the nucleus (94).  A unique spacer sequence 
that is located between its two kinase domains functions to maintain SRPK1 in the 
cytoplasm.  Deletion of the spacer sequence causes transport into the nucleus, resulting in 
phosphorylation of splicing factors (94-97).  One mechanism for maintaining SRPK1 in 
the cytoplasm is its interaction with co-chaperone proteins.  Upon cellular stress induced 
by osmotic shock, the co-chaperones dissociate, and SRPK1 enters the nucleus to 
phosphorylate SR proteins (98).  Further research is needed, however, to determine 
whether SRPK1 translocation occurs in response to other signals and if the same 
regulatory proteins are involved.  It is also important to understand how the activity of 
SRPK1 is regulated in the cytoplasm.    
Clk/Sty kinase (cdc2-like kinase/serine/threonine/tyrosine kinase) also 
phosphorylates SR proteins.  Humans express four isoforms of Clk/Sty, and they are 
members of the LAMMER family of protein kinases, named for the common LAMMER 
motif within the kinase domain (99).  Clk/Sty contains an RS domain itself, it 
phosphorylates serine residues in SR proteins, it is located in the nucleus, and co-
localizes to nuclear speckles with SR proteins. In general, Clk/Sty phosphorylates the 
same SR proteins that SRPK1 can and directly interacts with ASF/SF2, SRp20, SC35, 
SRp40, SRp55, and SRp75 (100, 101) but can phosphorylate other non-SR proteins (90).  
Clk/Sty tends to phosphorylate serines that are followed on the C-terminal side by 
arginines and prolines (90).  Over-expression of Clk/Sty causes ASF/SF2 to move from 
the speckles to the nucleoplasm, creating a diffuse appearance (91, 100).  Reciprocally, 
over-expression of a mutant Clk/Sty causes it and SR proteins to remain in speckles 
(100).  The phosphorylation of SR proteins by Clk/Sty also enhances their interaction 
with other splicing factors.  As an example, phosphorylation of ASF/SF2 via Clk/Sty 
enhances its interaction with U1 snRNP, inducing the splicing of a pre-mRNA in vitro 
(75). Clk/Sty can phosphorylate all 22 serine residues within the RS domain of ASF/SF2, 
while SRPK1 phosphorylation is restricted to ten serines within the N-terminal portion of 
the RS domain (92).  
The regulation of Clk/Sty activity is complex and poorly understood.  
Autophosphorylation on tyrosine residues is one mechanism by which the activity of 
Clk/Sty activity is regulated (102).  This regulation is quite complex as the combination 
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of autophosphorylated residues determines the SR proteins with which Clk/Sty can 
interact (103).  Additionally, different patterns of autophosphorylation cause the kinase to 
phosphorylate different patterns of residues in the RS domain of ASF/SF2 (103).  Clk/Sty 
is also phosphorylated by other kinases.  A recent study indicates that, in response to 
insulin treatment, Akt2 phosphorylates Clk/Sty, which activates the kinase and induces 
the phosphorylation of several SR proteins (89).  A better understanding of the regulation 
of Clk/Sty activity is critically needed.  Questions to be addressed are, how 
autophosphorylation and phosphorylation by other kinases is coordinated, is there a 
compartmentalization factor regulating Clk/Sty activity, what circumstances control 
autophosphorylation, and does Clk/Sty phosphorylate all SR protein members?  
Other kinases phosphorylate SR proteins besides SRPK1 and Clk/Sty.  In vitro 
phosphorylation studies indicate that PKC and PKA phosphorylate ASF/SF2 (90), 
although no cellular consequence is known.  Recently, it has been determined that insulin 
and other growth factors, through the action of Akt, induce phosphorylation of several SR 
proteins including SRp40, ASF/SF2, and 9G8, which has consequences upon the splicing 
of model pre-mRNAs (89, 104, 105).  These studies were some of the first to find a link 
between extracellular signals, SR protein phosphorylation, and splicing.   
 
SR proteins and phosphatases 
 
Dephosphorylation of proteins in the spliceosome is also necessary for the 
splicing process.  Initial in vitro splicing studies demonstrated that the activity of 
phosphatases upon snRNPs and ASF/SF2 is necessary for the first transesterification 
reaction of splicing (106, 107).  Further dephosphorylation is required for the protein 
rearrangements that occur during conversion from the first to the second step of 
transesterification (107).  These studies indicate that, in general, dephosphorylation of 
snRNPs and other proteins of the spliceosome is required for splicing catalysis and intron 
removal.  
SR proteins are also direct targets of phosphatases.  PP1 is an SR protein 
phosphatase that has been the most characterized.  In addition to the effect of 
dephosphorylation upon transesterification steps, dephosphorylation of SR proteins also 
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influences the outcome of splicing (108-110).  For example, an increase in ceramide in 
response to heat shock activates PP1 activity, which dephosphorylates SR proteins and 
impacts the splicing of several pre-mRNAs (109, 111), most likely through changes in 
protein-protein interactions.  Additionally, hypophosphorylation appears to be a 
prerequisite for the export from the nucleus into the cytosol of SR proteins bound to 
spliced mRNA via interaction with the TAP exporter (112, 113).  From there, 
phosphorylation via SRPK1 allows import back into the nucleus through their interaction 
with transportin-SR, and the cycle can begin again (114).  
Although very little research has directly addressed what the differences are or if 
there are differences between alternative and constitutive splicing processes, 
phosphorylation status of SR proteins may be one distinguishing factor.  Using well-
defined splicing substrates and purified ASF/SF2, the Manley group determined that 
dephosphorylation is required for its activity in constitutive splicing but not upon a 
substrate that undergoes activated splicing, i.e., regulated alternative splicing (115).  This 
study indicates that this differential requirement for phosphorylation upon two types of 
splicing substrates may be due to the ability of ASF/SF2 to interact with snRNPs.  
Specifically, more phosphorylation enhances the interaction of ASF/SF2 with the 70 kD 
subunit of U1 snRNP compared to mock phosphorylated ASF/SF2.  Differences in 
phosphorylation had no effect upon the ability of ASF/SF2 to bind to U2AF35, however 
(115).  This study provides the only direct comparison between the activity of SR 
proteins upon alternative and constitutive splicing substrates; thus, additional research is 
necessary to address this question and to determine if other differences exist between 
these two types of splicing modalities.    
Significant research is still needed to better understand the consequences of 
phosphorylation and dephosphorylation upon SR protein action.  One of the main 
obstacles to this area of research is the technical difficulty in detecting multiple 
phosphorylations within the highly repetitive RS domain; mass spectrometric analyses 
have been especially hindered.  Of note, most of the research in this area has utilized 
ASF/SF2 as the prototypical SR protein.  However, conclusions made about ASF/SF2 
may be inapplicable to other SR proteins.  
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Other mechanisms of the regulation of SR protein activity 
 
SR protein activity is regulated by several mechanisms besides covalent 
modifications of the RS domain, which includes changes in the amount of functional 
protein through transcriptional, pre-mRNA processing, and post-transcriptional 
mechanisms.  A change the amount of the mature protein can be mediated through 
alternative splicing.  Some SR proteins regulate their own expression, which is termed 
auto-regulation, and this occurs via alternative splicing that is coupled to NMD.  As an 
example, exon 4 of SRp20 is an alternatively spliced exon and contains a premature stop 
codon.  When SRp20 protein reaches a critical level, SRp20 binds to exon 4 of its own 
transcript and causes inclusion of exon 4.  This leads to inclusion of the premature stop 
codon and degradation of the pre-mRNA by NMD (84, 116).  ASF/SF2 antagonizes this 
series of events by binding to exon 4 and promoting exclusion of exon 4; and therefore, 
more SRp20 is translated (84).  Inclusion of exon 4 has been observed in cells that are 
serum starved, and treatment with serum has been shown to reverse this effect (117).  
This mode of regulation with splicing coupled to NMD appears to be common for 
splicing factors (SRp40, SC35, SRp75, SRp30c, and Tra2β are also regulated similarly) 
and allows homeostatic regulation of SR protein abundance (116, 118, 119). 
Another mechanism by which the expression of SR proteins is regulated is 
through proteosomal degradation.  SRp55 protein is degraded in the proteosome when it 
becomes hyperphosphorylated by Clk/Sty overexpression.  This is specific for SRp55 and 
not ASF/SF2 nor SC35, but the cellular consequences of this pathway are unknown 
(120).    
Very little is known about the transcriptional control of SR protein expression.  
One of the only examples is transcriptional regulation of SRp20.  Functional analysis of 
the promoter of SRp20 indicates that it is transcriptionally regulated by beta-
catenin/TCF4 in colon cancer cell lines (117, 121).    Overexpression of beta-
catenin/TCF4 in colon cancer cells activated transcription of endogenous SRp20 mRNA 
as well as a luciferase reporter driven by the SRp20 promoter.  The increase in 
accumulation of SRp20 mRNA and, subsequently, protein caused changes in alternative 
splicing of the CD44 pre-mRNA in these cells.  In a related observation, an increase in 
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expression of SR proteins has been observed in cancer cells and tumors (122), which may 
be related to an increase in transcriptional activity of these SR proteins as is observed 
with SRp20, but this remains to be tested.  Information regarding the transcriptional 
regulation of other SR proteins is lacking and may indicate that this is an unexplored area 
of research. 
 
SR Proteins in other areas of gene expression 
 
SR proteins are functionally linked to several other areas of gene expression 
besides pre-mRNA splicing, and the relationship between transcription and splicing has 
been an active area of research for many years.  As splicing occurs while the pre-mRNA 
is being transcribed from the DNA template, it has been a widely held and supported 
concept that the CTD of Pol II is involved in recruitment of SR proteins to target pre-
mRNAs.  Several reports indicate that the CTD, when phosphorylated, recruits some 
members of the SR protein family to bind to it (123-126), and a proteomic analysis of the 
Pol II complex revealed that SR proteins and the U1 snRNP were bound to it (127). The 
involvement of the CTD in recruitment of SR proteins is controversial, however.  Recent 
“splicing factor” ChIP (chromatin immunoprecipitation) experiments performed by the 
Neugebauer group indicate that there exists no direct link between the CTD and SR 
proteins.  In these experiments, protein-DNA and protein-protein complexes were 
crosslinked within living cells, the SR proteins were immunoprecipitated, and 
quantitative PCR was performed to amplify distinct regions of the gene of interest, 
indicating where upon the pre-mRNA SR proteins were located.  They show that when 
Pol II is paused at the transcription start site upon treatment with α-amantin, no SR 
proteins are “pre-loaded” upon the polymerase (71).  Only after active transcription has 
begun are SR proteins associated with Pol II, and this only occurs through the RNA 
intermediate, not protein-protein interactions (71).  The discrepancy between the data 
from the Neugebauer group and previous studies may be attributed to the rearrangement 
of protein interactions during immunoprecipitations.  In vivo crosslinking followed by 
immunoprecipitation, performed by the Neugebauer group, is mostly resistant to these 
confounding effects due to the covalent bonds between the proteins and nucleic acids.     
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Although evidence indicates that SR proteins aren’t directed to splice sites via 
their binding to the CTD of Pol II, many properties of transcription, in general, influence 
and may regulate the splicing process.  The speed of transcription can affect the outcome 
of alternative splicing (128, 129).  A mutant Pol II with a slow elongation rate results in 
an increase in the inclusion of an alternative exon in the fibronectin EDI exon (130).  
Natural pause sites for Pol II also are important for the regulation of alternative splicing 
of immunoglobulin mu and α-tropomyosin  (131, 132).  The rate of transcription may 
influence the secondary structure of the pre-mRNA and therefore, have consequences for 
the ability of splicing factors to bind to target sequences (133) or the rate of appearance 
of competing cis-acting sequences can also be important for the proper ordering of 
alternative splicing (132).  The rate of transcription can be affected by histone 
modifications, adding an additional layer of splicing regulation.  Conversely, 
transcriptional activators, which enhance elongation rate, influence the alternative splice 
site selection as well as modulate constitutive splicing (134, 135).  Different promoters 
driving expression of the fibronectin gene produce different alternative splicing events, 
indicating that promoter structure and/or transcription factors recruited to the promoter 
may be involved in splicing factor recruitment (136, 137).  These data indicate that the 
splicing of a particular transcript is complex and is likely regulated by not only splicing 
elements and factors but aspects of its transcriptional regulatory elements.  This level of 
complexity may make it nearly impossible to generalize the splicing regulatory process 
across all transcripts.  
In a reciprocal manner, SR proteins can influence transcription.  A recent research 
article indicates that SC35 depletion stalls Pol II elongation and transcription due to 
diminished recruitment of the kinase pTEFb and, consequently, reduced phosphorylation 
of serine-2 residues in the CTD (138).  This observation may be unique to SC35, 
however, because this SR protein exhibits DNA-binding properties that are absent from 
other SR proteins.       
SR proteins are involved in mRNA export out of the nucleus into the cytosol.  All 
SR proteins shuttle from the nucleus to the cytoplasm via their attachment to spliced 
mRNA except SC35, which doesn’t appear to leave the nucleus (71).  An active role in 
the export process has been demonstrated for SRp20, 9G8, and ASF/SF2, and these SR 
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proteins, upon their dephosphorylation within the spliceosome, enhance the export of an 
intronless mRNA by recruitment of the primary export protein, TAP (112, 139-141). 
Currently it is unknown which phosphatases dephosphorylate SR proteins during splicing 
catalysis prior to mRNA export and whether the effect upon transport is a function 
distinct from splicing or if it involves the recruitment of additional proteins.   
Due to the physical link between SR proteins and cytosolic mRNA, it is not 
surprising that SR proteins may also modulate translation.  ASF/SF2 is the only member 
of the SR protein family to be implicated in increasing cap-dependent translation 
efficiency.  An initial study indicates that ASF/SF2 associates with translating ribosomes 
and the binding of ASF/SF2 to a cytoplasmic reporter mRNA harboring an ASF/SF2 
binding site enhances translation of this mRNA and, recently, this has been extended to 
several other mRNAs (48, 142).  This effect was specific to ASF/SF2, which shuttles, and 
not for SC35, which doesn’t shuttle.  Interestingly, neither SRp20 nor 9G8 enhance cap-
dependent translation of reporter mRNAs despite their ability to shuttle and enhance 
mRNA export (142), though recent evidence suggests that SRp20 is a mediator of cap-
independent translation of a viral RNA (143).  ASF/SF2 appears to enhance translation 
initiation by maintaining the translation factor 4E-BP in a hyperphosphorylated state that, 
resultantly, is unable to bind to eIF4E and inhibit translation (144).  This occurs through 
the interaction of ASF/SF2 with mTOR kinase and/or the phosphatase PP2C (144).  In 
another mechanism for the enhancement of cap-dependent translation, ASF/SF2 
overexpression enhances the splicing and production of isoform 2b of MNK, which then 
phosphorylates eIF4E (122).  All of these effects of SR proteins upon mRNA 
processing/localization may indicate that the nuclear history of an mRNA may determine 
its fate in the cytoplasm (48).          
 
Alternative splicing regulation 
 
A main goal in the field of splicing is to understand how external stimuli affect 
the splicing of pre-mRNAs, which is generally termed regulated splicing.  In general, 
regulated splicing occurs through the interaction and competition between enhancer and 
silencer elements and proteins.  Perhaps, the best--characterized model of regulated 
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splicing in higher eukaryotes is the CD45 gene in T-cells.  CD45 is a transmembrane 
tyrosine phosphatase that undergoes alternative splicing in response to T-cell activation.  
Specifically, T-cell activation causes exclusion of exons 3,4, and 5 to create an inactive 
phosphatase that is necessary for the maintenance of T-cell homeostasis (145).  An ESS 
within exon 4 is one important cis regulatory element responsible for activation-induced 
exon skipping, and hnRNP LL is the trans-acting mediator (146, 147).  The expression of 
hnRNP LL is up-regulated in response to T-cell activation (146), but the signaling 
pathways that produce this response are still unknown.  This model exemplifies how 
activating signals can modulate the splicing of a particular pre-mRNA through a change 
in the expression of a splicing factor, which produces important consequences for cellular 
homeostasis.  Of particular note, recent evidence indicates that the increase in expression 
of hnRNP LL affects the splicing of a “program” of target genes that are responsible for 
T-cell activation (147).  This study demonstrates for the first time a “global” splicing 
regulatory system dependent upon a single splicing factor.    
A seminal paper in understanding how alternative splicing is regulated by growth 
factors was published in 2005 by the Srebrow group.  They showed that treatment of cells 
with growth factors caused an increase in phosphorylation within the RS domain of 
ASF/SF2 and 9G8, and Akt was the direct mediator of these phosphorylation events 
(104).  Additionally, the increase in phosphorylation of these two SR proteins coincided 
with an increase in inclusion of the EDA exon within a fibronectin mini-gene reporter.  
Furthermore, growth factors and Akt activation enhanced the translation efficiency of a 
reporter mRNA.  This study was groundbreaking in the field of splicing and greatly 
facilitated further study into the impact of other growth factors, such as insulin, upon 
splicing.  
The impact of insulin upon splicing processes is a developing field of study.  
Using exon–array analysis in drosophila cells, the Valcarcel group estimates that greater 
than 150 genes undergo alternative splicing upon insulin treatment, with genes involved 
in amino acid and carbohydrate metabolism being the second most affected family (148).  
Forty percent of the genes that are affected at the level of splicing are also regulated at 
the transcriptional level (148).  In higher eukaryotes, specific pre-mRNA transcripts that 
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undergo alternative splicing in response to insulin and other growth factors include 
PKCβII, the insulin receptor, and fibronectin EIIIB (149-151).   
The signaling mechanism involved in the effect of insulin upon PKCβII splicing 
is a prime example of how kinases affect the splicing process.  Work in the Cooper lab 
has determined that insulin treatment in muscle cells activates Akt2, which then directly 
phosphorylates SRp40, activating its splicing function upon PKC pre-mRNA (105).  The 
binding of SRp40 to PKC pre-mRNA induces exon inclusion and production of PKCβII 
splice product, which enhances glucose uptake.  As another layer of regulation, Akt2 also 
phosphorylates Clk/Sty in response to insulin; this activates Clk/Sty to phosphorylate 
SRp75, SRp55, and SC35 (89).  These studies indicate that insulin has the potential to 
affect the splicing of many target transcripts in different tissues in higher eukaryotes as it 
does in drosophila.  High-throughput screening technologies such as exon-junction 
microarrays and high throughput sequencing will enable global screening of splicing 
events that are induced by external stimuli.   
As the nutrient-responsive hormone, insulin, is a modulator of splicing, it follows 
that nutrients per se are also regulators of alternative splicing.  One of the only examples 
of a global view of alternative splicing in response to nutrients is in Saccharomyces 
cerevisiae.  Exon junction array analysis results indicate that amino acid starvation 
treatment reduces the splicing efficiency of several pre-mRNAs, and gene annotation 
identified pre-mRNAs coding ribosomal proteins were most severely affected (152).  
Additionally, ethanol treatment of the cells altered the splicing of a non-overlapping, 
discrete family of pre-mRNAs.   
Bioactive lipids are important regulators of many aspects of gene expression, but 
their role in splicing is just beginning to be evaluated.  Ceramide is one example of a 
bioactive lipid that regulates splicing.  An increase in ceramide activates PP1 activity, 
which reduces SR protein phosphorylation in cells (111); this has the potential to cause 
changes in splicing of many pre-mRNAs.  Ceramide directly regulates the splicing of two 
pre-mRNAs including caspase-9 and Bcl-x between their pro-apoptotic and anti-
apoptotic isoforms by the differential recruitment of splicing factors (153-155).  
Ceramide levels are elevated by several fatty acids including arachidonic acid and 
linolenic acid, which increase the metabolism of sphingomyelin to ceramide (156).  Fatty 
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acids also inhibit the splicing of the lipogenic enzyme, glucose-6-phosphate 
dehydrogenase (G6PD), which will be discussed in greater detail later in this chapter.   
 
Splicing and disease 
 
Aberrant splicing can result from mutations in cis elements or dysregulation of 
trans elements, which can lead to disease (83, 157, 158).  It is estimated that greater than 
50% of the point mutations that cause disease affect splicing (83).  One of the most 
studied cases of a point mutation disrupting splicing and resulting in disease is within the 
SMN2 gene (survival of motor neuron 2), a protein that is necessary for snRNP synthesis.  
A single point mutation within exon 7 leads to exon skipping creating an unstable protein 
that results in the disease called spinal muscular atrophy.  The point mutation is thought 
to disrupt an ESE to which ASF/SF2 binds and/or create an ESS to which hnRNP A1 
binds (159, 160).  Research efforts are currently underway to develop gene therapy to 
correct this splicing defect and have produced some promising results.  This example 
illustrates how the delicate balance between positive and negative regulators of splicing 
can go awry.       
Elevated levels of splicing factor proteins are also correlated with disease.  There 
is a strong correlation between increased expression of SR proteins and several different 
types of cancer.  Recently, the Krainer group directly demonstrated the pro-oncogenic 
properties of ASF/SF2 (122).  Overexpression of ASF/SF2 is tumorigenic in animal 
models, and this protein appears to transform cells via changing the splicing patterns to 
create pro-oncogenic and anti-apoptotic versions of proteins and also through non-
splicing mechanism involving mTOR (122, 161).  As these examples illustrate, the 
delicate balance between the amounts of trans-acting splicing factors and the fidelity of 




Splicing is a complex process, and all of the regulatory factors impinging upon it 
are just beginning to be understood.  As discussed above, constitutive and alternative 
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splicing are regulated by the interaction between cis and trans elements.  SR proteins are 
a major family of splicing regulatory proteins that generally enhance the formation of the 
spliceosome through several mechanisms.  Their activity is regulated through post-
translational modifications, sub-cellular localization, and changes in expression profiles.  
They have been shown to mediate the effect of extracellular signals upon the splicing of 
pre-mRNA targets in a few examples, but this area is poorly understood.  G6PD is a 
model mRNA that undergoes differential splicing in response to starvation and refeeding 
in whole animal.  This model has the potential to produce a better understanding of the 
impact of nutrients upon the activity of SR proteins and target pre-mRNAs.      
 
The regulation of G6PD splicing by nutrients 
 
G6PD oxidizes glucose-6-phosphate to 6-phosphogluconolactone in the first rate-
determining step of the pentose phosphate pathway, which is also known as the hexose 
monophosphate shunt and the phosphogluconate pathway.  This reaction reduces NADP+ 
to NADPH + H+ which then provides reducing power for biosynthetic reactions such as 
fatty acid synthesis, cholesterol synthesis, and amino acid synthesis (162). The NADPH + 
H+ is also necessary for maintaining glutathione in its reduced form for protection against 
reactive oxygen species.  The ribose-5-phophate produced by the pentose phosphate 
pathway is utilized in nucleotide biosynthesis.   
As glucose-6-phosphate is a substrate for both glycolysis and the pentose 
phosphate pathway, cellular needs determine where the sugar is directed.  This regulation 
occurs through the change in activities of phosphofructokinase, one of the main 
regulatory enzymes of the glycolytic pathway, and G6PD.  Phosphofructokinase activity 
is inhibited when the ATP/AMP ratio is high and by citrate, which slows the flux through 
the glycolytic pathway.  High levels of NADPH and fatty acids inhibit G6PD activity, 
and, thus, the flux through the pentose phosphate pathway decreases.   A change in the 
expression of G6PD is the mechanism by which its activity is regulated in the metabolic 
tissues of the liver and adipose tissue, and its expression is regulated by nutrients and 
hormones. 
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The process of fatty acid biosynthesis involves conversion of excess dietary 
carbohydrate to the fatty acid palmitate.  The carbon required for fatty acid biosynthesis 
is derived from mitochondrial citrate from the TCA cycle, which crosses the inner 
mitochondrial membrane to the cytosol.  There, ATP-citrate lyase converts the citrate to 
acetyl-CoA and oxaloacetate.  The acetyl-CoA proceeds to fatty acid synthesis, while the 
oxaloacetate returns to the mitochondria either as malate or pyruvate through the activity 
of the citrate-malate-pyruvate shuttle in the cytosol.  Malic enzyme, which converts 
malate to pyruvate in the citrate-malate-pyruvate shuttle, also provides about 50% of the 
NADPH + H+ required for fatty acid biosynthesis, and G6PD and 6-phosphogluconate 
dehydrogenase, the second enzyme of the pentose phosphate pathway, provide the other 
half of the reducing equivalents (162).  The first committed step of fatty acid biosynthesis 
is performed by acetyl-CoA carboxylase, carboxylating acetyl-CoA to malonyl-CoA.  All 
of the subsequent steps of palmitate synthesis occur through the action of fatty acid 
synthase, which is a dimer of identical 250 kD proteins containing multiple enzyme 
functions (Figure 5).  The palmitate that is produced can be further elongated and 
desaturated to produce other types of fatty acids.  Desaturation is performed by steroyl-
CoA desaturase.  Fatty acids are esterified to glycerol, forming triacylglycerol and can be 
transported from the liver to adipose tissue within VLDL.        
The family of lipogenic enzymes consists of the following members: G6PD, malic 
enzyme, ATP-citrate lyase, acetyl-CoA carboxylase, and fatty acid synthase.  The activity 
of these enzymes is regulated coordinately in liver and adipose tissue so that activity is 
low when the energy status and substrate availability is low, such as during a period of 
fasting.  Alternatively, when nutrients exceed immediate energy needs, such as after a 
high carbohydrate meal, activity of these enzymes is enhanced to convert this energy to 
stored energy in the form of triacylglycerol in adipose tissue.  The end-product of fatty 
acid synthesis, fatty acids, also inhibits lipogenic flux.  The target of this inhibition is 
acetyl-CoA carboxylase, which can be regulated with covalent modification, in which 
phosphorylation inhibits its activity, providing immediate reduction in fatty acid 
synthesis.  This phosphorylation is performed by AMP-activated kinase that is triggered 
to phosphorylate acetyl-CoA carboxylase when the AMP/ATP ratio is high.  The
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activities of most of the other lipogenic enzymes are regulated by changes in 
expression, with transcriptional regulation by sterol-response element binding protein 
being the most common mechanism.  Transcriptional changes are regulated by hormonal 
cues from insulin and glucagon as well as dietary compounds such as polyunsaturated 
fatty acids and glucose. 
G6PD expression, however, is regulated at a post-transcriptional step (163). When 
mice are fasted for 12 hr and then refed a diet that is high in carbohydrate and low in fat, 
hepatic G6PD expression is induced by 12-fold or greater compared to fasted mice (164, 
165).  There is a similar response in primary rat hepatocytes that are treated with insulin 
compared to glucose alone (166).  On the other hand, G6PD expression is 60% lower in 
the livers of mice that are fed a diet containing 6% polyunsaturated fat compared to a low 
fat (1%), high carbohydrate diet (164).  Mirroring this effect in primary culture, 
arachidonic acid attenuates the insulin-induced increase in G6PD expression in rat 




Figure 5.  Fatty Acid Synthesis and the Metabolic Pathways that Contribute 
Substrates and Reducing Equivalents to it. 
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Despite large changes in mRNA abundance, the transcription rate of the G6PD 
gene does not differ between dietary treatments (165, 167, 168).  In addition, other points 
of RNA processing, including polyadenylation rate and length of the poly (A) tail, are not 
altered in refed or starved mice (168).  The regulatory point affected by polyunsaturated 
fatty acids is pre-mRNA splicing.  Arachidonic acid treatment reduces the efficiency of 
splicing by causing retention of intron 11 (167), which reduces the amount of mature 
G6PD mRNA that can be exported to the cytosol for translation.  At the molecular level, 
recent work in our lab indicates that arachidonic acid treatment inhibits expression of 
G6PD mRNA by interfering with the action of insulin.  Specifically, arachidonic acid 
treatment results in the activation of p38 MAP kinase, which causes IRS-1 to become 
phosphorylated at serine 307, thereby reducing activation of the phosphoinositide 3-
kinase pathway (169).   
We have identified an ESS that governs G6PD splicing repression during 
treatment with arachidonic acid.  A reporter system was used to define the G6PD 
regulatory sequence in primary rat hepatocytes.  Several reporters were constructed that 
contained different regions of the G6PD driven by the CMV promoter.  These reporters 
were transfected into primary rat hepatocytes and the cells were treated with insulin or 
insulin plus arachidonic acid.  The inhibition of expression of each reporter in response to 
arachidonic acid was evaluated with RNase protection assays.  These experiments 
determined that exon 12 was necessary for the inhibitory effect of arachidonic acid as 
reporters containing exon 12 were inhibited similarly to endogenous G6PD mRNA (167, 
170).  Thus, the reporter system was an accurate model of the endogenous G6PD mRNA.  
To further define the regulatory sequence within exon 12, nine constructs were 
synthesized that contained exons 7-13, their intervening introns, and a span of 10-nt 
block mutations (AAGCATGCAA) within exon 12.  Upon expression in primary 
hepatocytes, three constructs with mutations spanning nucleotides 43 to 72 of exon 12 
lacked appreciable inhibition of splicing in the presence of arachidonic acid compared to 
insulin alone (170)(~10% only).  Since this region is important for inhibition of splicing, 
we suggest that it contains an ESS.   
In vitro splicing assays provided additional evidence that exon 12 contains an 
ESS.  RNA substrates designed with and without exon 12 were in vitro-transcribed in the 
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presence of 32P-labeled CTP to label the RNA and incubated with HeLa nuclear extract, 
which provides the necessary splicing proteins.  Substrates lacking exon 12, such as exon 
8-intron 8-exon 9, exon 10-intron 10-exon 11, and exon 10-intron 11-exon 11 exhibited 
splicing (60% to 70% spliced).  However, exon 11-intron 11-exon 12, exon 10-intron 10-
exon 12, and exon 8-intron 8-exon 12 were not spliced (less than 5% spliced) (170).   
Next, spliceosome assembly assays were performed to determine at what step the 
assembly of the spliceosome was being inhibited.  These experiments are identical to in 
vitro splicing assays except that the reactions are stopped at several different time points 
with the addition of heparin.  The progress of spliceosome assembly through time is 
visualized by the characteristic sizes of protein-RNA complexes on polyacrylamide gels.  
Specifically, the H and E complexes exhibit the fastest gel mobility, followed by the A 
complex, and finally the largest complexes are the B and C complexes, which migrate 
together and form just prior to splicing catalysis.  These experiments indicated that the 
exon 11- intron 11- exon 12 substrate, compared to positive controls, exhibited reduced 
formation of the A complex and completely lacked formation of the B and C complexes.  
The A complex forms when U2 snRNP binds to the intron; thus, this indicates that the 
ESS represses splicing of intron 11 by preventing the recruitment of U2 snRNP (170).   
In addition to this region containing an ESS, experiments indicated that it also 
contains an ESE.  A deletion of the regulatory element in exon 12 from the exon 11- 
intron 11- exon 12 substrate did not confer splicing activity upon this substrate in an in 
vitro splicing assay (170).  This indicated that deletion of the regulatory element not only 
removed an ESS but also an ESE.  As juxtaposed ESE and ESS elements are a common 
regulatory mechanism in splicing, and since our data supported this concept, we 
hypothesized that the regulatory element contains both an ESS and an ESE that regulate 
differential splicing in response to nutrients. 
 In order for a cis-acting ESS to produce an effect on splicing, trans-acting 
proteins must bind to the sequence and influence the formation of the spliceosome.  We 
have identified putative splicing repressor proteins that bind to the regulatory region of 
exon 12 through UV crosslinking analysis and RNA affinity techniques.  RNA 
oligonucleotides corresponding to 15 nucleotide spans of exon 12 were incubated with 
starved and refed mouse liver nuclear extract, the oligonucleotides and nuclear proteins 
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were crosslinked, and the complexes were treated with RNase to remove unprotected 
bases.  The proteins were run on a SDS-PAGE gel and visualized by phosphorimaging to 
detect their sizes.  The oligonucleotide spanning nucleotides 65-79 of exon 12 
consistently was bound by proteins of 60 and 37 kDa molecular weight (171), and similar 
results were found with RNA affinity experiments.  Through liquid chromatography-
tandem mass spectrometry, the 60 kDa band was identified as hnRNP K and L, and the 
37 kDa band was identified as hnRNP A2/B1 (170, 171).  HnRNP A2 and B1 are two 
closely related proteins that only differ by an additional 12 amino acid residues in B1.  A 
peptide was sequenced in the tandem mass spectrometry experiment that corresponded to 
this 12 amino acid region, which indicated that B1 was present; however, we could not 
exclude the possibility that A2 was also present as the two proteins are otherwise 
identical.  Thus, these hnRNPs bind specifically to the 50-79 nucleotide region that 
overlaps the splicing regulatory element region, nucleotides 43-72 of exon 12, and we 
hypothesize that they are necessary for the repression of splicing of G6PD.   
Evidence for the role of these hnRNPs in the repression in G6PD splicing was 
observed with liver nuclear extract from starved and refed mice.  Western analysis was 
performed after the nuclear proteins were purified with the oligonucleotide corresponding 
to the splicing regulatory element.  The western analysis confirmed that hnRNP K, L, and 
A2/B1 bound to the splicing regulatory element.  We additionally observed a 60-70 % 
reduction in binding of these proteins to the 50-79 oligonucleotide in nuclear extracts 
from the livers of refed animals, in which G6PD splicing was enhanced, compared to the 
extracts from the livers of starved animals, in which splicing was inhibited (171).  Thus 
our lab has demonstrated that hnRNP K, L, and A2/B1 bind in greater abundance to the 




 Understanding the activity of the splicing machinery is affected by external 
stimuli is a crucial area of splicing research.  As discussed above, very few examples 
exist in the literature that directly address this question.  G6PD is an excellent model with 
which to study the how nutrients regulate the splicing process differentially.  We have 
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identified a splicing regulatory element within exon 12 of the G6PD transcript, which 
exhibits ESS and ESE characteristics.  Since we observe an increase in splicing efficiency 
in response to insulin treatment and refeeding and reduced splicing efficiency of G6PD in 
response to starvation and polyunsaturated fatty acids, we hypothesize that this 
differential splicing is due to competition between closely juxtaposed ESS and ESE 
elements within the splicing regulatory element.  As previously characterized inhibitory 
splicing proteins bind to the regulatory element during starvation when splicing is 
inhibited, we hypothesize that SR proteins bind to the element during refeeding when 
splicing is enhanced.  Therefore, we hypothesize that SR proteins are more active during 
refeeding than during starvation and that this change in activity is due to changes in 
phosphorylation of the RS domain of these SR proteins.  The data presented herein 
support our hypothesis that nutrients and insulin affect the activity of SR proteins upon 
the model pre-mRNA, G6PD, and this change in activity most likely occurs through 
changes in phosphorylation of SR proteins.  Additionally, we provide evidence that 
SRp20 binds to the regulatory element of G6PD and enhances splicing of this transcript.  
These data are novel and have implications for the splicing of other transcripts in 
response to dietary changes.  This knowledge is important for understanding the complex 
molecular mechanisms of the nutritional regulation of gene expression and diseases 
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Dietary status and individual nutrients and hormones regulate alternative splicing 
of eukaryotic mRNAs. We have established a model for this type of regulation by 
analyzing the abundance of glucose-6-phosphate dehydrogenase (G6PD) mRNA in liver 
in which its splicing is enhanced during refeeding/insulin treatment and splicing is 
attenuated during starvation/treatment with polyunsaturated fatty acids. Differential 
splicing of G6PD mRNA involves a regulatory element in exon 12, which contains a 
putative exonic splicing enhancer sequence. The primary goal of the current studies was 
to determine whether nutritional status affects the activity of SR proteins and to establish 
changes in SR protein activity as a mechanism for nutritional regulation of mRNA 
splicing. Consistent with the G6PD regulatory element containing an exonic splicing 
enhancer, SRp20 and SRp75 bound to the regulatory element, and binding was enhanced 
by refeeding, corresponding to an increase in splicing. Refeeding also enhanced the 
binding of SR proteins to the G6PD transcript in vivo as identified by chromatin 
immunoprecipitation. In hepatocytes, insulin stimulated phosphorylation of several SR 
proteins, while addition of arachidonic acid inhibited this effect.  In vitro splicing assays 
and siRNA-mediated knock-down of SRp20 demonstrated that SRp20 enhances splicing 
of G6PD. Together, these data establish that nutritional regulation of SRp20 activity is 
involved in the differential splicing of the G6PD transcript in response to nutrients; in 
addition, nutritional regulation of other SR proteins suggests that this regulatory 




Greater than 90% of human transcripts undergo alternative splicing which can 
alter many functional aspects of the resulting proteins, including, but not limited to, the 
amount expressed, the binding properties of the protein, and the presence or absence of 
specific domains within the protein (1, 2).  Changes in splicing patterns are involved in 
development and maintaining the phenotype of somatic cells (2).  Splicing is regulated by 
cis-acting elements and trans-acting factors; therefore, mutations in these elements or 
changes in the activity of trans-acting proteins will alter cellular function and potentially 
lead to disease (3).  In order to recognize the contribution of splicing to cellular function, 
it is necessary to understand how splicing is regulated in different cell types by 
extracellular signals. 
 Serine-arginine rich (SR) proteins are a family of trans-acting splicing factors that 
activate splicing (4).  The canonical SR protein family members include SRp75, SRp55, 
SRp40, ASF/SF2, SC35, 9G8, and SRp20.  These proteins enhance the splicing process 
by binding to exonic splicing enhancers (ESEs) to recruit U1 snRNP, U2AF35, and U2 
snRNP to intronic splice sites and/or by inhibiting the binding of negative regulators of 
splicing (5, 6).  SR proteins play a critical role in the splicing of alternatively included 
exons and are also essential for constitutive exon splicing when the surrounding intron 
has weak splice sites (4).  The structural characteristic of SR proteins is one or two RNA 
recognition motifs and an arginine-serine rich (RS) domain.  The RS domain is 
phosphorylated on serines, which enhances the interaction of SR proteins with other 
splicing factors (4).  Phosphorylation also regulates intra-cellular and intra-nuclear 
localization of SR proteins, which controls their access to target transcripts (7).  As the 
RS domain contains many serines that can be phosphorylated and are substrates of 
several kinases, SR proteins are central players that mediate the impact of extracellular 
signals upon the splicing process (8-10).  The involvement of hormones and other 
extracellular signals in regulating splicing factor activity is a poorly understood area. 
 The overriding question of our research is to understand how nutrients affect the 
splicing process, and we utilize a model gene, glucose-6-phosphate dehydrogenase 
(G6PD) to address this question.  G6PD is an enzyme that is integral to the process of de 
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novo lipogenesis in liver and adipose tissue by its generation of reducing equivalents in 
the form of NADPH + H+ (11).  Its expression is regulated in these tissues by nutrients, 
and this regulation occurs by changes in the rate of splicing of the G6PD pre-mRNA (12).  
In this regard, in rodents, starvation or consumption of a diet containing polyunsaturated 
fatty acids reduces the efficiency of intron removal from the primary transcript (13), 
subsequently leading to reduced expression of the enzyme, and, therefore, fewer reducing 
equivalents are available for lipogenesis.  This is a form of regulated alternative splicing 
called intron retention, and it shares cis-acting elements and trans-acting factors with 
other forms of alternative splicing.  G6PD pre-mRNA containing retained introns 
adjacent to exon 12 accumulates in the nucleus when splicing is inhibited.  Feeding a 
high carbohydrate, low fat diet to rodents after a short-term fast, which is termed 
refeeding, induces efficient splicing, greater expression of the enzyme, and an increase in 
lipogenic capacity compared to animals that are fasted (12).  These in vivo feeding 
experiments are recapitulated in primary rat hepatocytes in culture in which treatment 
with insulin induces the accumulation of spliced G6PD mRNA, and the polyunsaturated 
fatty acid, arachidonic acid, attenuates mRNA splicing (13-15).  A splicing regulatory 
element in exon 12 of the G6PD transcript mediates the effect of nutrients upon the 
splicing of this pre-mRNA (15). 
 In the current set of experiments we sought to determine whether the activity of 
SR proteins changes in response to nutrients and also identify candidate SR proteins that 
mediate the increase in splicing of G6PD that occurs in response to refeeding and insulin 
treatment.  Using G6PD as a prototype, we determined that refeeding increased the 
binding of SR proteins to the splicing regulatory element both in vitro and in vivo.  
Furthermore, insulin increased the nuclear content of phosphorylated SR proteins, while 
arachidonic acid reduced this effect.  Within the family of SR proteins, SRp20 was 
specifically involved in the regulation of G6PD mRNA splicing.  Overall, these findings 
provide not only a greater understanding of stimuli and signaling events that affect the 





 Previously, we have determined that an RNA regulatory element necessary for 
differential splicing is located within nucleotides 43-72 of exon 12 of G6PD mRNA, and 
this regulatory element contains an exonic splicing silencer (15).  The ESS in this 
sequence is necessary for the inhibitory effect of arachidonic acid upon splicing in 
primary rat hepatocytes, it suppresses splicing of chimeric splicing substrates, and it 
binds three members of the hnRNP family (K, L, A2/B1) coincident with splicing 
attenuation (15, 16).  Deletion of the 43-72 nucleotide regulatory element fails to restore 
splicing in in vitro assays, suggesting the presence of an ESE.   
 
Refeeding increases the binding of SR proteins to the splicing regulatory element.   
The goal of the current series of experiments was to determine if SR protein 
binding was relevant to nutritional stimulation of splicing and to determine which SR 
proteins are involved in the splicing of G6PD in response to nutritional cues.  We 
hypothesized that if SR proteins mediate the increase in splicing that is observed during 
refeeding and insulin treatment, then their binding to the regulatory element would be 
enhanced under these dietary treatments.  An RNA affinity assay was performed to first 
identify which SR proteins bound to the element and, second, to determine if the binding 
was regulated by nutritional state (Fig. 1).  Nuclear extracts were prepared from the livers 
of rats that had been starved for 18 h or starved and then refed a high carbohydrate diet 
for 16 h.  Refeeding increases the accumulation of G6PD mRNA an average of 8-fold 
above that observed in the livers of starved animals, and this was confirmed in these 
livers (12, 17 and data not shown).  In the RNA affinity assay, RNA oligonucleotides 
corresponding to the splicing regulatory element (nucleotides 43-72 of G6PD exon 12) 
were attached to agarose beads, and used to affinity purify RNA binding proteins from 
the fasted and refed nuclear extracts.  An RNA oligonucleotide corresponding to a region 
of exon 12 outside of the regulatory element (control region; nucleotides 79-93) was used 
to control for non-specific binding of proteins to RNA, and the beads alone were included 
to detect any background binding contributed by the beads.  Binding proteins were eluted 
with a step-wise gradient of buffers containing an increasing amount of KCl, and SR 
proteins were detected using western analysis (Fig. 1).  To screen for the binding of 
multiple SR proteins in a single blot, the SR protein antibody 16H3 was used, which 
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detects both the phosphorylated and non-phosphorylated forms of SRp75, SRp55, SRp40, 
and SRp20.  As shown in Fig.1A, the low salt wash eluted SRp40, SRp55, and SRp75 
from the splicing regulatory element, the control region, and beads in both dietary 
treatments, but only SRp75 maintained a persistently strong interaction with the 
regulatory element RNA as indicated by its elution in the higher salt buffers.  SRp20 was 
undetectable in this blot due to its low abundance in liver compared to the other three SR 
proteins (Fig. 1C).  To address this, a monoclonal antibody that detects SRp20 was used.  
Similar to SRp75, SRp20 was eluted with the lowest salt wash from all of the affinity 
columns and from both dietary groups (Fig. 1B).  SRp20 remained bound to the 
regulatory element and was eluted at higher salt concentrations, but was not detected 
bound to the control RNA region or the beads alone.  The persistent interactions of 
SRp20 and SRp75 with the regulatory element indicate a specific interaction between 
these trans-acting splicing regulators and the cis-acting RNA element from exon 12 of 
G6PD mRNA.  Although SRp40 and SRp55 are also present in nuclear extract (Fig. 1C), 
they do not bind to the splicing regulatory element (Fig. 1A).   
 Notably, nutritional status of the animal regulated the binding of these SR 
proteins.  Refeeding enhanced the binding of SRp20 to the RNA element by 3-fold.  It 
also caused a small, but reproducible increase in the binding of SRp75 to the element 
(20%).  The increase in binding upon refeeding was evident in spite of equal amounts of 
these two SR proteins in the nuclear extracts from both fasted and refed livers (Fig. 1C).  
The coincident changes in G6PD mRNA accumulation and SR protein binding in refed 
rat livers is consistent with our hypothesis that SR proteins enhance the splicing of G6PD 
mRNA in response to nutritional status.  Thus, SRp20 and SRp75 are candidate SR 
proteins involved in this regulation. 
If the interaction between SR proteins and the splicing regulatory element are 
important for the nutritional regulation of splicing, then these interactions should occur in 
intact cells.  To determine if these interactions occurred within intact liver cells and 
during starvation and refeeding, we used the chromatin immunoprecipitation (ChIP) 
assay.  ChIP is commonly used for detecting DNA-binding proteins bound to specific 
nucleic acid sequences within the chromatin (18); however, ChIP is becoming a standard 
technique for detection of RNA-protein interactions during transcription of the nascent 
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mRNA (19-21).  This technique detects the binding of splicing factors to target pre-
mRNA sequences via their close proximity to chromatin during the transcription and 
processing of mRNA (22).  The co-transcriptional occurrence of splicing (23) and the 
close proximity of splicing factors and pre-mRNA to the chromatin (24) enable cross-
linking between RNA-bound splicing factors and the adjacent chromatin.  After cross-
linking, the protein of interest is immunoprecipitated and the DNA sequences 
corresponding to the RNA region of interest are amplified by real-time PCR, which is 
used as a measure of the protein occupancy on the pre-mRNA.  
ChIP was performed in livers from either starved or starved and then refed mice 
to detect the occupancy of phosphorylated SR proteins on G6PD pre-mRNA.  The 
monoclonal antibody 1H4 was used that detects phosphorylated RS domains, and, 
therefore, recognizes all members of the SR protein family.  Available antibodies for 
specific SR proteins do not perform well in ChIP assays, and, thus, this strategy is not 
used (21).  The 1H4 antibody also cross-reacts with the phosphorylated C-terminal 
domain of RNA polymerase II (Pol II; 25).  To correct for this, ChIP was also performed 
with an antibody against Pol II.  Because the ChIP technique detects interactions between 
the RNA binding protein and nearby DNA, primers were designed to amplify a region 
encompassing the regulatory element and sequences upstream in the exon.  We 
hypothesized that refeeding, which induces the splicing of G6PD, would increase the 
binding of phosphorylated SR proteins to the regulatory element of G6PD.  As shown in 
Fig. 2, refeeding significantly induced the binding of phosphorylated SR proteins to the 
splicing regulatory element by 1.8-fold above that observed during fasting.  Dietary 
treatment did not alter the occupancy of Pol II across this region of exon 12 indicating 
that a true increase in SR protein binding was occurring (Fig. 2).  The lack of change in 
Pol II occupancy on the G6PD chromatin is consistent with the absence of transcriptional 
regulation of this gene (17).  Next, we measured the occupancy of SR proteins on exon 2 
of phosphoenolpyruvate carboxykinase (PEPCK) pre-mRNA, which is transcriptionally 
regulated and induced during starvation (26).  Fasting induced the binding of 
phosphorylated SR proteins to PEPCK pre-mRNA by 2.7-fold over refeeding; however, 
starvation also increased the binding of Pol II to the PEPCK gene, consistent with the 
increase in transcriptional activity of this gene (26).  Thus, the enhanced binding of SR 
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proteins to the G6PD regulatory element is not due to a generalized effect of refeeding 
upon the binding of SR proteins to RNA elements.  Additionally, hnRNP M 
immunoprecipitation was performed as a negative control because previous experiments 
have determined that this RNA binding protein fails to bind to the splicing regulatory 
element in vitro (15).  Binding of hnRNP M to the regulatory element was low, and this 
binding was not altered by the nutritional status of the animal.  The ChIP assay, thus, 
extended the RNA affinity assay data and demonstrated that, in liver, refeeding induces 
the binding of SR proteins to the RNA element of G6PD.  These ChIP data are quite 
novel as they are the first to demonstrate that SR proteins bind to target pre-mRNAs 
differentially in response to metabolic signals in the whole animal. 
 
SiRNA depletion of SRp20 decreases G6PD mRNA accumulation. 
Binding of SR proteins to the RNA element is consistent with the element being 
an ESE (27).  The demonstration of regulated binding in intact tissues suggests a 
functional enhancer activity for the SR proteins.  To address the function of SRp20 and 
SRp75 in regulating splicing of G6PD mRNA in cells, we used a loss-of-function 
approach.  SiRNA-mediated knock-down of SRp20, SRp75 and SRp55 was performed, 
and the effect upon expression of a G6PD splicing reporter and endogenous G6PD was 
evaluated.  SRp55 knock-down was included as a negative control because this protein 
did not bind to the G6PD regulatory element (Fig. 1A).  HeLa cells were used because 
they are easy to transfect, and the pattern of SR protein binding to the G6PD regulatory 
element is similar to liver (data not shown).   
SiRNAs targeting SRp20, SRp55, and SRp75 each faithfully depleted its 
respective protein and had little effect upon non-target SR proteins (Fig 3A).  SRp20, 
SRp55, and SRp75 were reduced by 87%, 93%, and 94%, respectively, compared to the 
non-targeting siRNA (NT).  Knock-down of SRp20 resulted in a small but reproducible 
decrease in SRp75, SRp40 and SRp30a/b, but this decrease was much less than the 
decrease in SRp20 itself.  The expression of SR proteins involves not only auto-
regulation of their own splicing but also regulation by other family members (28, 29); 
thus, some decrease is not unexpected. This western analysis was performed with 
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mAb104, which detects phosphorylated SR proteins (Fig. 3A, top panels), but antibodies 
detecting total amounts of these SR proteins showed similar results (data not shown).   
The splicing reporter used in these experiments, pβ-gal ex12-ex13 (Fig. 3B), 
contains exon 12, intron 12, exon 13, and the 3’ UTR of G6PD ligated to the β-
galactosidase gene.  This design allowed us to evaluate the role of these SR proteins upon 
splicing regulated by the element in exon 12 with minimal interference by ESEs in other 
exons of the G6PD pre-mRNA.  Additionally, expression of this reporter is regulated in a 
manner similar to endogenous G6PD in primary rat hepatocytes treated with insulin and 
arachidonic acid (15).  Reduction in SRp20 protein expression inhibited splicing of the 
reporter mRNA by 44% in comparison to cells transfected with NT siRNA (Fig. 3C, 
upper panels).  In contrast, loss of SRp75 expression did not inhibit expression of the 
reporter mRNA and, in fact, enhanced expression 1.9-fold compared to NT siRNA.  
Knock-down of SRp55, which does not bind to the regulatory element, also enhanced 
expression (1.4-fold).  An increase, rather than a decrease or no effect, in reporter 
expression was unexpected and may reflect peculiarities of the reporter RNA sequence. 
As further investigation of the role of SRp20 in splicing of G6PD, we evaluated 
the effect of the SR protein knock-down upon the expression of the endogenous G6PD 
transcript.  The interaction of splicing regulatory sequences and their associated binding 
proteins in the regulation of basal G6PD splicing is conserved in HeLa cells.  
Additionally, the expression of G6PD in these cells is quite robust, which suggests that 
“splicing activation” is the default.  SRp20 protein depletion resulted in a 30% reduction 
in expression of endogenous G6PD (Fig. 3C, middle panels).  This decrease in 
endogenous RNA splicing was remarkable as some cells most likely were not transfected 
with siRNA, and the 13 exons of the G6PD transcript undoubtedly contain multiple 
splicing regulatory elements that interact with other SR proteins.  SRp55 also 
significantly reduced the expression of this transcript by 26%, but SRp75 had no 
significant effect.  The effect of SRp55 upon endogenous G6PD expression most likely 
indicates its importance in other regions of the pre-mRNA because it did not bind to the 
splicing element in the RNA affinity assay (Fig. 1A).  Depletion of SRp20 or the other 
SR proteins did not affect the expression of cyclophillin B, a negative control, indicating 
a specific effect upon splicing of G6PD mRNA. 
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SRp20 enhances splicing of exon 12-containing mRNA. 
To verify that SR proteins and, specifically, SRp20 are direct enhancers of G6PD 
splicing, we tested SR protein function in the in vitro splicing assay.  The G6PD pre-
mRNA substrate containing exon 11, intron 11, and exon 12 (IVS 11-12) splices 
inefficiently (9%) as compared to 22% splicing with another G6PD splicing substrate 
containing exon 8, intron 8, exon 9 (IVS8-9; Fig. 4A).  This is due to the strong ESS 
within the regulatory element of exon 12 (15).  To restrict the overriding effect of the 
ESS on splicing in this assay, we used a limiting amount of HeLa nuclear extract, which 
reduced the amount of silencing proteins (hnRNPs) and SR proteins contributed by the 
nuclear extract.  This limiting amount of nuclear extract didn’t support splicing compared 
to the full complement of nuclear extract (Fig. 4B, compare lanes 1 and 2 of both panels) 
and, thus, provided a baseline to which SR proteins were added to test for their ability to 
enhance splicing.  Addition of a mixture of SR proteins to the assay enhanced the splicing 
of both IVS 8-9 and IVS 11-12 (Fig. 4B, compare lanes 2 and 3 of both panels).  SR 
proteins enhanced splicing of the exon 12-containing substrate by 3-fold.  An apparent 
decrease in the substrate RNA was consistently observed when the extent of splicing in 
the assay was low.  As this pattern of bands was observed numerous times, the 
differences in substrate mRNA between lanes cannot be attributed to loading errors; 
therefore quantitation of the spliced product without correction by the substrate RNA 
band was appropriate. We attribute this decrease to degradation of the substrate in the 
absence of splicing.  This may have involved non-specific actions of RNase or may 
reflect targeted degradation of the intron-containing transcript by the nuclear exosome 
(30).  Alternatively, the differences in intensity of the pre-mRNA observed between lanes 
may be attributed to the occurrence of two bands of similar size when splicing was 
observed, one corresponding to unspliced substrate and the other corresponding to the 
intron lariat attached to the 3’ exon, an intermediate in the splicing reaction.   
 Because SRp20 binds to the regulatory element and knock-down of SRp20 
inhibits G6PD expression, we asked if SRp20 per se could enhance splicing of IVS 11-
12.  SRp20 was purified from Sf9 cells following baculovirus infection.  The presence of 
SRp20 was confirmed with western analysis (Fig. 4D), and it comprised 36% of the total 
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protein as detected with Coomassie staining (data not shown).  Addition of SRp20 
increased splicing of IVS 11-12 by 2-fold or more (Fig. 4C).  To confirm that SRp20 
caused the increase and not co-purifying Sf9 proteins, a control protein mixture was 
added to the splicing assay.  This mixture is a protein preparation from Sf9 cells that were 
infected with a baculovirus expressing SC35, but purification of SC35 was unsuccessful.  
As such, SC35 constituted less than 5% of the total protein of this mixture (data not 
shown).  The control protein mixture did not enhance splicing of either substrate (Fig. 
4C, lane 4 of both panels).  In contrast to the specific effect of SRp20 on IVS11-2 
splicing, it did not enhance splicing of the IVS 8-9 RNA substrate (Fig. 4C, lanes 2 and 3 
of left panel).  Thus, splicing activation by SRp20 is sequence specific.  In sum, SRp20 
appears to be a necessary splicing activator, enhancing expression of G6PD and doing so 
through the exon 12 regulatory element. 
 
Phosphorylation of SR proteins changes with insulin and arachidonic acid 
treatment. 
We have determined that refeeding enhances the binding of SRp20 to the 
regulatory element.  We sought to further understand how nutrients and hormones might 
affect SR protein activity and contribute to the regulated binding of SRp20 in the liver.  
Phosphorylation of the RS domain of SR proteins is an essential step regulating SR 
protein activity (31).  The goal of the current experiment was to determine if there was a 
change in the phosphorylation status of nuclear SR proteins due to hormones and 
nutrients.  Treatment of primary rat hepatocytes with insulin and a high glucose medium 
reflects the humoral milieu of the refed state (32).  While glucagon is a hormone 
associated with metabolic regulation during starvation, it does not decrease expression of 
G6PD (33).  Starvation is also accompanied by lipolysis and an increase in circulating 
free fatty acids (34). Treatment of hepatocytes with the non-esterified fatty acid, 
arachidonic acid, is our model for starvation-induced lipolysis.  Fatty acids cause a 
decrease in G6PD expression in the hepatocytes, and the time course of this decrease 
reflects the decrease in G6PD expression during starvation (14, 17).  Changes in G6PD 
mRNA abundance by these treatments are caused by changes in the splicing of the 
primary transcript (13).  
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Incubation of rat hepatocytes with insulin and high glucose medium significantly 
enhanced the amount of phosphorylated SRp20, SRp30a/b, and SRp40 in nuclear extracts 
as compared to media alone (Figs. 5 B and C).  The increase in phosphorylation of these 
proteins coincided with a 3-fold increase in G6PD mRNA abundance (Fig. 5A).  There 
was a trend toward an increase in phosphorylation of SRp55 and SRp75 in response to 
insulin, but it did not reach the level of significance.  In contrast to the effect of insulin 
alone, addition of arachidonic acid to the medium significantly attenuated the amount of 
phosphorylated SRp40 and SRp20 by 50-80%.  This decrease in SR protein 
phosphorylation coincided with a 50% decrease in G6PD mRNA abundance.  Equal 
amounts of protein were used for the analysis as indicated by the control protein, lamin 
A/C (Fig. 5B).  Notably, insulin increased and arachidonic acid decreased the amount of 
phosphorylated SRp20 to a greater extent than any other SR protein.  The large changes 
in phosphorylation are consistent with a role for this protein in nutrient-induced splicing 
regulation.  This change in the amount of phosphorylated SR proteins in response to 
insulin and arachidonic acid may reflect a phosphorylation/dephosphorylation switch, a 
change in expression of these SR proteins, or movement of SR proteins to and from the 
nucleus.  Regardless, this experiment indicates that insulin and arachidonic acid modulate 
the nuclear content of phosphorylated SR proteins, which enhances their regulatory 
capacity in the splicing process.  Furthermore, the changes in SRp20 content coincide 




Understanding how external signals such as nutrients and hormones affect the 
splicing process introduces a new paradigm for regulating cellular function.  Because the 
majority of genes undergo alternative splicing, this process is central in determining the 
protein composition of cells.  External stimuli and hormones can exert an effect upon 
splicing by increasing or decreasing the expression of splicing factors and/or by changing 
their activity (8, 10, 35, 36).  G6PD was one of the first pre-mRNAs identified to be 
regulated at the step of splicing by nutritionally-responsive hormones and nutrients (37).  
In this report, we’ve identified SR proteins as targets in the nutrient regulation of 
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splicing.  SR proteins bind to the exon 12 regulatory element of G6PD pre-mRNA in 
intact liver, and refeeding enhances their binding.  Of the SR proteins, SRp20 enhances 
the splicing of G6PD mRNA, and loss of SRp20 decreased G6PD expression.  
Furthermore, the phosphorylation state of SRp20 is regulated by nutrients and the 
nutritionally regulated hormone, insulin.  Therefore, SRp20 is a candidate splicing 
activator for the nutritional regulation of G6PD expression.  
SRp20 has defined roles in directing alternative splicing as well as mRNA 
transport to the cytosol (38-40).  Our data suggest that SRp20 is having a direct effect 
upon splicing of G6PD mRNA rather than upon transport alone because it enhanced 
removal of intron 11 within the in vitro splicing substrate IVS 11-12 (Fig. 4C).  The 
inefficient splicing of exon 12-containing substrates is caused by an inhibition of the 
formation of the A complex (15).  This intermediate in spliceosomal catalysis involves 
the recruitment of U2 snRNP to the branch point and formation of a stable interaction 
between U2 snRNP and the mRNA (41).  SR proteins can enhance spliceosomal 
formation by recruitment of U2 snRNP (42).  This suggests that SR proteins would be 
required for G6PD splicing.  Thus, SRp20 binding to exon 12 and activation of splicing 
in vitro is consistent with this role of SR proteins in spliceosome formation. 
The binding of SRp20 to the regulatory element would not be predicted based on 
the presence of a canonical binding site.  SRp20 binding sites that have been identified 
are CU and CA rich (43-45).  Current computer ESE prediction software do not identify 
SRp20 binding sites within the regulatory element encompassing nucleotides 43-72 of the 
93 base exon 12, but putative SRp20 binding sites conforming to known consensus 
sequences occur just 5’of the regulatory element and overlapping the 3’ end of the 
element  (Splicing Rainbow, Morais and Valcarcel; ESE finder (46, 47)).  In contrast, this 
same software predicts binding of proteins such as SRp40 and SRp55; binding of these 
proteins was not detected in our assays despite their abundance in the nuclear extract 
(Fig. 1C). ESE prediction software uses sequences determined by SELEX or 
bioinformatics to establish the comparison sequence and are, thus, isolated from the 
complexity of the cellular environment. Thus, these predictions must be followed up with 
functional analyses.  The global diversity of SRp20 binding sites has not been established 
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experimentally.  Within the G6PD regulatory element, CA rich regions appear to be 
sufficient to support binding. 
Most remarkable is the large change in SR protein binding with refeeding.  The 
increased binding was observed in intact liver using ChIP.  This is the first demonstration 
of regulated binding of SR proteins to mRNA in response to nutritional status.  The 
specific interactions of SRp20 and SRp75 with the G6PD regulatory element were 
determined in vitro using an RNA affinity assay.  While nutritional status altered the 
binding of both SRp20 and SRp75 to the splicing regulatory element, only the binding of 
SRp20 was relevant for increased splicing of G6PD mRNA.  In this regard, knock-down 
of SRp75 failed to decrease expression of G6PD mRNA (Fig. 4C).  The involvement of 
SRp20 in the nutritional regulation of splicing is further supported by the regulation of 
SRp20 phosphorylation in response to insulin and arachidonic acid.  Upon 
phosphorylation, SR proteins move from the cytoplasm to the nucleus and from sites of 
concentration within the nucleus, called speckles, to nascent RNA at transcription sites 
(7).  In addition, phosphorylation enhances binding to RNA regulatory elements and 
protein-protein interactions (31, 48).  SR proteins bound to the G6PD regulatory element 
were phosphorylated based on their detection with a phosphorylation-specific antibody 
(Fig. 2).  This binding of SR proteins in the fed state is consistent with our earlier data 
demonstrating the opposite pattern of binding by splicing silencing proteins during 
starvation.  Members of the hnRNP family of splicing silencing proteins, K, L and 
A2/B1, bind to the G6PD regulatory element in the starved state, and this binding is 
decreased by refeeding (16).  Competition between SRp20 and splicing silencers has 
been demonstrated in regulation of the alternative splicing of the insulin receptor (40).  A 
similar competition for binding may be part of the regulatory mechanism controlling 
G6PD splicing in response to nutrients and nutritional status.   
A considerable body of literature supports a broad role of insulin in alternative 
splicing.  Splicing-sensitive microarrays performed with drosophila cells demonstrate that 
greater than 150 genes undergo alternative splicing in response to insulin treatment (49).  
In mammalian cells, insulin regulates alternative splicing of PKCβII (50). The effect of 
insulin upon alternative splicing of PKCβII is coincident with an increase in the 
phosphorylation of SRp40 (9).  Insulin-mediated increases in SRp40 activity involve both 
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direct phosphorylation by Akt2 and indirect mechanisms via phosphorylation of Clk/Sty, 
an SR protein kinase, by Akt2 (10).  The coincident increase in G6PD splicing and SR 
protein binding with refeeding likely involves a regulatory role for insulin because insulin 
is required for the diet-mediated increases in G6PD expression (37).  In hepatocytes in 
culture, insulin increases G6PD mRNA and increases SR protein phosphorylation, 
including phosphorylation of SRp20.  
Previous evidence from our lab demonstrates that the increase in splicing of 
G6PD that we observe with insulin treatment is due to an increase in its signaling through 
PI3K and Akt; whereas arachidonic acid treatment attenuates insulin’s signaling by 
inhibition of PI3K activity (51).  Arachidonic acid decreases the amount of 
phosphorylated SR proteins and causes a coincident decrease in the accumulation of 
G6PD mRNA (Fig. 5).  In particular, these changes were observed with SRp20, the SR 
protein most relevant for regulating splicing of G6PD.  The presence of a consensus 
sequence for Akt phosphorylation in the RS domain of SRp20 suggests that this protein 
can be a target of insulin action directly.  Insulin action could also be indirect via 
stimulation of Clk/Sty.  Consistent with this concept, the phosphorylation-specific 
antibody used in these studies detects phosphorylations by SR protein kinases including 
Clk/Sty, suggesting an increase in their activity. Identifying the relevant kinases involved 
in SR protein phosphorylation in intact liver and primary rat hepatocytes cultures is the 
subject of on-going investigations in the laboratory.  The decrease in phosphorylation of 
SR proteins during arachidonic acid treatment may not be the result of reduced kinase 
activity alone, but alternatively, may be due to an increase in phosphatase activity during 
this treatment.  The bioactive lipid, ceramide, reduces phosphorylation of SR proteins via 
activation of PP1 (52), and arachidonic acid has been shown to induce ceramide 
production from sphingomyelin in HL-60 cells (53).  The findings that insulin enhances 
the amount of phosphorylated SR proteins in the nucleus of hepatocytes and that 
refeeding enhances the binding of SR proteins to this nutritionally regulated target are 
significant intrinsically.  SR proteins enhance the splicing of multiple genes, and, thus, 
nutritional status could impact the splicing of many transcripts in addition to G6PD.   
In sum, these data indicate that nutrients and nutritional status induce changes in 
the activity of SR proteins, which impacts the splicing of a model metabolic gene.  These 
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data provide further support for the role of insulin in pre-mRNA processing, providing 
another layer of control over gene expression beyond its well-described effects upon 
transcription.  We hypothesize that other pre-mRNA transcripts are regulated by nutrients 
at the step of splicing, as nutrient signaling affects the abundance of nuclear 
phosphorylated SR proteins and the binding capacity of SR proteins.  These results have 
important implications to fully understand the process by which our metabolic organs 
respond appropriately to nutrients and hormones and provide a new paradigm for nutrient 
regulation of cellular function. 
 
Materials and Methods 
 
All animal experiments were conducted in conformity with the Public Health 
Service policy on Humane Care and Use of Laboratory Animals, additionally; the 
Institutional Animal Care and Use Committee of the Division of Laboratory Animal 
Resources at West Virginia University approved all experimental procedures. 
 
Animal care and liver nuclear extract preparation - Male Sprague-Dawley rats (200-300 
g) were either fasted for 24 h or fasted for 24 h and then refed a fat free/high glucose diet 
containing 1% safflower oil as a source of essential fatty acid (fat free/high glucose USB 
diet, #1810092, Purina Mills) for 16 h prior to sacrifice.  Liver nuclear extracts were 
prepared by the method of Schibler et al. (54) with modifications.  Briefly, liver nuclei 
were isolated by immediately homogenizing the livers with a Thomas homogenizer in 
buffer I (0.25 M sucrose, 60 mM KCl, 15 mM NaCl, 15 mM Hepes, pH 7.4, 2 mM 
EDTA, 0.5 mM EGTA, 0.15 mM spermine, 0.5 mM spermidine, 14 mM β-
mercaptoethanol, 1 mM Na3VO4, 1 mM PMSF, 50 mM NaF, 1 mM benzamidine, 0.5 
µg/ml leupeptin, 2 µg/ml aprotinin, 10 mM β-glycerophosphate, and 0.1 mM Na2MoO4).  
The homogenate was layered over a cushion of buffer II (buffer I containing 0.75 M 
sucrose), and centrifuged for 10 min at 100 x g to produce a crude nuclear pellet.  The 
pellet was further homogenized in buffer III (buffer I except 2 M sucrose, 0.1 mM 
EDTA, and 0.1 mM EGTA).  This homogenate was layered over buffer III, topped with 
mineral oil, and centrifuged 1h at 155,000 x g.  Nuclear proteins were extracted from 
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nuclei as per the Dignam protocol (55) in extraction buffer containing 20 mM Hepes, pH 
7.9, 25% glycerol, 350 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT and the 
same concentrations of protease and phosphatase inhibitors used in buffer I and stored at 
-80°C until use.  
 
RNA affinity assay - RNA oligonucleotides corresponding to nucleotides 43-72 and 79-93 
of exon 12 of G6PD were purchased from IDT. One thousand pmol of each RNA 
oligonucleotide was attached to adipic acid dihydrazide-agarose beads (Sigma) using our 
modification (16) of the methods of Langland et al. (56) and Caputi et al. (57).  Each 
RNA-bead complex (250 µl) was mixed with starved or refed rat liver nuclear extract in a 
binding reaction containing 250 µg of protein in 500 µl of buffer (20 mM Hepes, pH 7.4, 
9% glycerol, 70 mM KCl, 0.2 mM EDTA pH 8.0, 1000 ng/ml tRNA, 2.5 mM ATP, 2 
mM MgCl2, and 0.2 mM DTT).  The binding reactions were incubated at 30°C for 30 
min, after which, the bead mixtures were placed into columns (5-mL plastic columns 
with fritted ends), flow-through was eluted with gravity drip, the RNA-bead complexes 
were washed with 500 µl of wash buffer containing no salt (20 mM Hepes, pH 7.4, 5% 
glycerol, 0.2 mM EDTA pH 8.0, and 0.1 mM DTT), and proteins were eluted with 
gravity drip in a step-wise manner with 1 ml volumes of wash buffer, as listed above, 
containing an increasing concentration of KCl (100 mM, 150 mM, 250 mM, 500 mM, 
750 mM, 1000 mM).  Each elution was collected into a separate tube and concentrated 
and de-salted with Amicon® Ultra centrifugal filter devices (3,000 MWCO, Millipore).  
Equal volumes (50 % of total volume) of concentrated protein from each sample were 
separated on 10% SDS-PAGE gels, transferred to PVDF membranes (Bio-Rad), and 
probed with SRp20 antibody (Zymed) or 16H3 antibody (Zymed), which detects SRp75, 
SRp55, SRp40 and SRp20.  After incubation with secondary antibodies conjugated to 
horseradish peroxidase (Bio-Rad), signals were detected with ECL Plus (GE Healthcare), 
and visualized on a Typhoon 9410 Imager (GE Healthcare) and with X-ray film. 
 
Animal care and chromatin immunoprecipitation (ChIP) assay - Six-week old C57BL/6 
mice were fed a high carbohydrate diet (described above, Purina Mills) for one week.  
Mice in the starved group were fasted for 18 h prior to sacrifice.  Mice in the refed group 
 71 
were fasted for 18 h, refed the high carbohydrate diet for 12 h, and then sacrificed.  The 
crosslinking reaction and ChIP assay are modifications of existing protocols (58, 59).  
Immediately after sacrifice, the livers were removed and immersed in four volumes of 
phosphate buffered saline containing 1.25% formaldehyde, 1 mM Na3VO4, 1 mM PMSF, 
50 mM NaF, 1 mM benzamidine, 0.5 µg/ml leupeptin, 2 µg/ml aprotinin, 10 mM β-
glycerophosphate, 30 mM p-nitrophenyl phosphate, and 0.1 mM Na2MoO4, minced, and 
mixed by rotation for 12 min at room temperature. The crosslinking reaction was stopped 
with the addition of glycine to a final concentration of 125 mM.  Samples were 
homogenized in a dounce homogenizer (8 strokes, loose pestle), incubated 15 min on ice, 
and then centrifuged 5 min at 1500 x g at 4°C.  The pellets were resuspended in 3 
volumes of cell lysis buffer (5 mM Hepes, pH 8.0, 85 mM KCl, 0.5% NP40, and protease 
and phosphatase inhibitors as listed above), homogenized in a dounce homogenizer (15 
strokes, loose pestle), incubated on ice for 15 min, and centrifuged at 3500 x g for 5 min 
at 4°C.  The pellets were resuspended in 1 volume of nuclear lysis buffer (1% SDS, 50 
mM Tris-HCl, pH 8.1, 10 mM EDTA, and protease and phosphatase inhibitors as listed 
above), homogenized with a dounce homogenizer (5 strokes, loose pestle), aliquoted into 
1-ml volumes, and incubated on ice for 10 min.  Samples were sonicated with continuous 
pulse (output 2) in 4 x 15 sec bursts.  The probe was chilled between each pulse.  
Samples were then cleared by centrifugation at 19,000 x g for 10 min, supernatants were 
reserved and diluted 5-fold with dilution buffer (0.01% SDS, 1.1% Triton X-100, 16.7 
mM MOPS, pH 7.3, 1.2 mM EDTA, 167 mM NaCl, and the same concentrations of 
protease and phosphatase inhibitors as listed above), and stored at -80°C until 
immunoprecipitation steps. 
 For the immunoprecipitation, protein A/G agarose beads (Santa Cruz) were 
washed 5 times in dilution buffer and blocked in dilution buffer containing 5 mg/ml BSA 
and 250 µg/ml sonicated salmon sperm DNA.  An aliquot from each ChIP sample was 
removed prior to immunoprecipitation to serve as the “input”.  ChIP samples were then 
pre-cleared with blocked agarose beads for 2 h with rotation, centrifuged to pellet the 
beads, and supernatants were placed into fresh tubes to which the following 
immunoprecipitation antibodies were added (7.5 to 15 ug): phosphorylated SR (1H4, 
Zymed), hnRNP M (Zymed), and RNA polymerase II (Covance).  The “no antibody” 
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control was treated identically to immunoprecipitations except it received no primary 
antibody.  Samples were immunoprecipitated overnight with rotation at 4°C, after which 
samples were rotated with blocked beads for 2 h, and washed once with each of the 
following buffers (1 ml of each): low salt buffer (20 mM MOPS, pH 7.3, 150 mM NaCl, 
2 mM EDTA, 0.1% SDS, 1% Triton X-100), high salt wash buffer (20 mM MOPS, pH 
7.3, 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton-X 100), LiCl wash buffer (10 
mM MOPS, pH 7.3, 1 mM EDTA, 0.25M LiCl, 1% NP40, 1% deoxycholate), and finally 
2 times in a buffer containing 10 mM MOPS, pH 7.3 and 1 mM EDTA.  All wash buffers 
contained protease and phosphatase inhibitors as listed above.  The immunoprecipitated 
proteins were eluted from the agarose beads with 0.1M NaHCO3, 1% SDS.  
Immunoprecipitated and input samples were reverse crosslinked with 200 mM NaCl at 
65°C for 6 h, digested with proteinase K (180 µg/ml) for 1 h at 45°C, phenol/chloroform 
extracted, ethanol precipitated, and resuspended in 10 mM Tris, pH 8.0, 0.1 mM EDTA. 
 Quantitative real-time PCR was performed with QuantiTect probe PCR reagents 
(Qiagen) with the following primers and dual-labeled probes (IDT): G6PD exon 12 
regulatory element (F: 5’- ACCTCCATCCTACACTGTATCC-3’, R: 5’-
CTGTTAGCTTCCATCCTTCCCT-3’, probe: 5’-/56-
FAM/TGGCGTATCTTCACACCACTGCTGCACAA/3BHQ1/-3’) and PEPCK (F: 5’-
TTCGTGGAAGGCAATGCTCA-3’, R: 5’-TCTTCAGCTTGCGGATGACA-3’, probe: 
5’-/5IAbFQ/TATATCCACATCTGCGATGGCTCCGAGGA/36-FAM/-3’).  The amount 
of DNA that was immunoprecipitated relative to the amount present in total input 
chromatin was determined with the following formulas: ΔCt=Ct(input)-Ct(IP), % total = 
2ΔCt x 1.7, where 1.7% is the percent that the input chromatin represents of the total 
chromatin (60).  This value was then normalized to the signal found in the “no antibody” 
control.  
 
siRNA transfection - One day after passage, HeLa cells (2 X 105) were transfected with 
75 nM siRNA pools using 7.5 µl of TransIT-siQUEST® Transfection Reagent (Mirus) in 
MEM containing 10% FBS. All siRNAs targeting a particular mRNA were siGENOME 
SMARTpools (Dharmacon) consisting of 4 siRNA duplexes.  The siRNA pool for SRp20 
contained the following duplexes: GAGUGGAACUGUCGAAUGG, 
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GGACUGUAAGGUUUAUGUA, CGAAGUGUGUGGGUUGCUA, 
CGAGAUGAUUAUCGUAGGA.  The siRNA pool for SRp55 consisted of the 
following duplexes: GCAGAAAUAUUAGGCUUAU, 
GCGACAAGCAGGUGAAGUA, CGUACAGAAUACAGGCUUA, 
GGAUACAGCAGUCGGAGAA.  The siRNA pool for SRp75 contained the following 
duplexes: GGCAAGACCUAAAGGAUUA, GAAGUGGCCGAGAUAAAUA, 
GAAUCACGCUCCAGAUCAA, GCAAAGACCAAGCUGAAGA.  SiGENOME non-
targeting siRNA pool #1 was used as the negative control.  Media was changed 24 h after 
siRNA transfection.  The cells were incubated an additional 24 h and then were 
transfected with 3 µg of the splicing reporter, pβ-gal ex12-ex13 using 6 µl of TransIT®-
LT1 Transfection Reagent (Mirus) in complete MEM.  Twenty-four h later, total RNA 
and whole-cell protein extracts were collected.  RNA was extracted with TRI Reagent® 
(Applied Biosystems), DNase digested, and expression of the splicing reporter or 
endogenous mRNAs was quantified by real-time RT-PCR (ICYCLER, Bio-Rad) using 
the QuantiTect SYBR Green kit (Qiagen).  Real-time RT PCR primers were as follows: 
pβ-gal ex12-ex13 (F: 5’-ACGACTCCTGGAGCCCGTCA-3’, R: 5’-
CTGTGGGGCCGCGGCTGC-3’), human cyclophillin B (F: 5’-
GCACAGGAGGAAAGAGCATC-3’, R: 5’-CTTCTCCACCTCGATCTTGC-3’), 
human G6PD (F: 5’-GCTGAGATTTTGCCAACAGG-3’, R: 5’-
GCATCACGTCCCGGATGA-3’).  The amount of each mRNA was calculated using a 
relative standard curve.  Whole-cell protein extracts were collected in lysis buffer 
containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EGTA, 1% Triton-X 100, 1 
mM Na3VO4, 1 mM NaF, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 
mM PMSF, and a mixture of protease inhibitors (Complete Mini, Roche).  Equal amounts 
of protein (2.5 µg) were separated on 10% SDS-PAGE gels, transferred to PVDF 
membranes (Bio-Rad), and probed with SRp20 antibody (Zymed), culture supernatant 
from hybridoma cells expressing mAb104 (ATCC), or Lamin A/C antibody (Cell 
Signaling).  After incubation with secondary antibodies with horseradish peroxidase 
conjugation, signals were enhanced with ECL Plus (GE Healthcare), visualized on a 




In vitro splicing assays - In vitro splicing assays were performed as described previously 
(15) with slight modifications.  Briefly, the positive control splicing assays contained 
60% (v/v) HeLa nuclear extract (Promega), and splicing complementation experiments 
contained a limiting amount of nuclear extract (10%) to which the remaining volume was 
replaced with buffer D (20 mM Hepes-KOH, pH 7.6, 100 mM KCl, 0.2 mM EDTA, 5% 
glycerol, 0.5 mM PMSF, and 0.5 mM DTT) or SR proteins, which were suspended in 
buffer D.  The appropriate volume for the limiting amount of nuclear extract was 
empirically determined based on the volume that demonstrated negligible splicing in the 
absence of supplemented SR proteins (data not shown).  All components of the buffer 
were maintained constant across all splicing reactions.  Quantitation of the % splicing in 
the in vitro splicing assays in Fig. 3A, was performed as described previously (15) using 
ImageQuant where the splice product was divided by the sum of the splice product and 
the pre-mRNA signal.  Quantitation of the relative level of splicing in Fig. 3B and 3C 
consisted of measuring the intensity of the spliced product with ImageQuant, which was 
then normalized to the splice product observed with the positive control (full complement 
of nuclear extract).   
The mixture of SR proteins was purified from HeLa cells via the method of 
Zahler (61).  Purified SRp20 containing a His tag was obtained from Sf9 cells infected 
with an SRp20 baculovirus (a gift from J.G. Patton (62) and prepared by Virusys 
Corporation), and the preparation consisted of 36% SRp20.  The control protein mixture 
was an impure protein preparation from Sf9 cells infected with SC35 baculovirus; this 
preparation contained a very low amount of SC35 (<5% of total protein) as a result of 
problems in the purification procedures (data not shown).  The preparation controls for 
the addition of Sf9 proteins per se to the splicing reaction.  To determine the purity of 
each protein preparation, an aliquot was separated on a 12% SDS-PAGE gel, stained with 
colloidal Coomassie (Invitrogen), and quantified with ImageJ (NIH).  Western analysis 
was also performed upon the purified SRp20 sample with the SRp20 antibody (Zymed).        
 
Hepatocyte culture and nuclear extract preparation - Male Sprague-Dawley rats (150-
250 g) were maintained on a chow diet until they were fasted 16 h prior to isolation of 
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hepatocytes via the method of Seglen as previously described (14).  Hepatocytes (3 x 106) 
were plated in collagen-coated 60 mm dishes containing Hi/Wo/BA medium (Waymouth 
MB752/l plus 20 mM Hepes, pH 7.4, 0.5 mM serine, 0.5 mM alanine, 0.2% bovine 
serum albumin) plus 5% newborn calf serum (37 °C, 5% CO2).  After 4 hr, the cells were 
washed and plated in the same media lacking serum, and a matrigel overlay was added 
(0.3 mg/ml; BD Pharmingen).  Sixteen h later, the media was replaced with fresh media 
alone or media containing 80 nM insulin or 80 nM insulin plus 175 uM arachidonic acid 
conjugated to bovine serum albumin (4:1 ratio; 63).  Twelve h later, the media was 
replaced with media of the same composition.  Twenty-four h after the initial treatment, 
nuclear extracts (from 6-12 plates per treatment) were prepared via the method of 
Dignam et al. (55), and western analysis was performed as described above and 
quantified with ImageQuant TL (Molecular Dynamics) and ImageJ (NIH).  At the same 
time point, total RNA was collected as described above under “siRNA transfection”. 
Real-time RT PCR was performed with QuantiTect probe PCR reagents (Qiagen) with 
the following primers and dual-labeled probes (IDT): G6PD (F: 5’-
TATGTCTATGGCAGCCGAGGT-3’, R: 5’-GCAGAGTGCAGATGGTGTAAG-3’; 
G6PD probe, 5’-FAM/CCACAGAGGCAGATGAGCTGATGAAGAA/3BHQ-3’) and β-
actin (F: 5’-GATGACCCAGATCATGTTTGAGACC-3’ R: 5’- 
GGAGTCCATCACAATGCCAGTG-3’, probe: 5’- 
HEX/CCCAGCCATGTACGTAGCCATCCAGG/3BHQ-3’). Cyclophilin B expression 
was detected with the Qiagen Quantitect SYBR Green reverse transcription-PCR system 
and the following primers: (F: 5’-CGTGGGCTCCGTTGTCTT-3’, R: 5’-
TGACTTTAGGTCCCTTCTTCTTATC-3’).  Cyclophillin B and β-actin were used as 
endogenous reference genes, and the amount of G6PD was calculated using relative 
standard curves.  
 
Statistical Analyses – For Figs. 2 and 3C, statistical comparisons were made using 
Student’s t-test, and significance was defined as P < 0.05.  For 5C, one-way ANOVA was 
performed, and, if the overall P-value was significant (P < 0.05), Dunnett’s Multiple 
Comparison Test was performed to make pairwise comparisons to the insulin treatment 
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(media alone vs. insulin and insulin vs. insulin + arachidonic acid; GraphPad Prism, 
version 4.0).  
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Figure 1.  Refeeding enhances the binding of SRp20 and SRp75 to the splicing 
regulatory element.  An RNA affinity assay was performed with the following RNA 
oligonucleotide-bead complexes: regulatory element (nucleotides 43-72 of exon 12 of 
G6PD), control region (nucleotides 79-93 of exon 12 of G6PD), and beads alone which 
were used to pull-down proteins from nuclear extracts prepared from livers of starved and 
refed rats.  Proteins were eluted in buffers containing an increasing concentration of KCl 
as indicated with the triangle, and proteins were detected with immunoblots. (A) 
Immunoblot with 16H3 antibody; the protein marker (kDa) is indicated to the right of 
each gel. I, input representing 2.5 µg of nuclear protein.  (B) Immunoblot with SRp20 
antibody. (C) The protein inputs (10 µg) used in the affinity assay detected with 16H3 
antibody.  Due to the low abundance of SRp20 when detected with 16H3, another blot 
with 20 µg of nuclear extract is shown beneath.  SR proteins are identified by size and 
indicated on the right.  Each RNA affinity assay is a representative of n = 3 assays 
performed using two independent nuclear extract preparations.     
 
Figure 2.  Refeeding increases the binding of phosphorylated SR proteins to the 
regulatory element of G6PD in vivo.  Chromatin immunoprecipitation assay (ChIP) was 
performed in livers of starved and refed mice with the following antibodies:  
phosphorylated-SR protein (phospho-SR), hnRNP M, and RNA polymerase II (Pol II).  
The occupancy of each of these proteins upon exon 12 of the G6PD mRNA and exon 2 of 
the PEPCK mRNA was measured using real-time PCR.  The values for each are the 
amount on the test sequence relative to the “beads alone” control within each dietary 
group.  The “*” symbol indicates P < 0.05.  Repetitions were as follows for G6PD: IP of 
phospho-SR n=3; IP of hnRNP M n=3; IP of Pol II n=2; and for PEPCK: IP of phospho-
SR n=5; IP of hnRNP M n=3; IP of Pol II n=2.  
 
Figure 3.  SiRNA-mediated depletion of SRp20 reduces the splicing of a G6PD reporter 
and the endogenous G6PD mRNA. (A) Whole cell lysates were prepared from HeLa cells 
24 h after transfection with siRNA pools targeting SRp20, SRp55, SRp75, as well as the 
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non-targeting (NT) control.  Western analysis was performed with antibodies against 
multiple SR proteins (mAB104), SRp20, and lamin A/C.  (B) Schematic representation of 
the pβ-gal ex12-ex13 splicing reporter.  The CMV promoter drives expression of the 
reporter RNA.  Mouse DNA containing exon 12, intron 112 and exon 13 through the end 
of the G6PD gene was ligated to β-galactosidease.  (C) The expression of the transiently 
transfected G6PD reporter (pβ-gal ex12-ex13), endogenous G6PD gene, and cyclophillin 
B gene was measured by real-time RT-PCR following knock-down with SRp20, SRp55, 
SRp75, and non-targeting (NT) siRNA.  The “*” indicates a significant difference (P < 
0.05).  Repetitions were as follows: pβ-gal ex12-ex13 expression following treatment 
with SRp20 siRNA n=6, SRp55 siRNA n=9, SRp75 siRNA n=9; endogenous G6PD 
expression following treatment with SRp20 siRNA n=12, SRp55 siRNA n=9, SRp75 
siRNA n=9; endogenous cyclophillin B expression following treatment with SRp20 
siRNA n=6, SRp55 siRNA n=9, SRp75 siRNA n=9.  
 
Figure 4.  SRp20 enhances splicing of RNA containing the exon 12 regulatory element. 
(A) In vitro splicing assays were performed using the RNA substrates:  IVS 8-9 (exon 8, 
intron 8, and exon 9) and IVS 11-12 (exon 11, intron 11, exon 12) and the maximum 
amount of HeLa nuclear extract.  The “*” indicates the spliced product.  A representative 
assay is shown in which all samples were run on the same gel, but intervening lanes were 
removed from the image; this experiment has been repeated multiple times.  I, input; NE, 
nuclear extract (B) In vitro splicing assays were performed utilizing IVS 8-9 and IVS 11-
12 and a mixture of purified SR proteins.  The following treatments were used: maximum 
amount of nuclear extract (lane 1), limiting nuclear extract as described in the text (lane 
2), limiting nuclear extract plus the mixture of purified SR proteins (lane 3).  A 
representative gel is shown.  To the right of the gel are cartoons indicating the location of 
the unspliced substrate and the spliced product.  Below each gel is the relative level of 
splicing, which is the amount of spliced product normalized to the positive control (lane 
1) and is an average of n = 3 independent splicing assays. (C) In vitro splicing assay of 
IVS 8-9 and IVS 11-12 were performed utilizing purified SRp20.  The following 
treatments were used: maximum amount of nuclear extract (lane 1), limiting nuclear 
extract (lane 2), limiting nuclear extract plus SRp20 (lane 3) and limiting nuclear extract 
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plus control Sf9 protein mixture (lane 4). Below each gel is the relative level of splicing, 
which is the amount of spliced product normalized to the positive control (lane 1) and is 
an average of n = 3 independent splicing assays.  (D) Immunoblot of the purified His-
tagged SRp20 produced in Sf9 cells detected with the SRp20 antibody. 
 
Figure 5.  Insulin and arachidonic acid regulate the amount of phosphorylated SR 
proteins in the nuclei of primary rat hepatocytes.  (A) Primary rat hepatocytes were 
incubated in high glucose (27.5 mM) medium alone (NA), insulin (I; 80mM), or insulin 
plus arachidonic acid (I+AA; 175 µM).  After 24 h, total RNA was isolated and the 
amount of G6PD mRNA was measured by real-time RT-PCR.  The value for the amount 
of G6PD mRNA with insulin treatment (1.5 ± 0.3) was set at 1 and the values for the NA 
and I+AA treatments are expressed relative to the insulin treatment.  The data represent 
n= 3 independent hepatocyte isolations.  (B) Nuclear extract was prepared from the 
hepatocytes treated as described in part A.  The extracts were subjected to western 
analysis using an antibody against phosphorylated SR proteins (mAB104) and lamin A/C.  
A representative immunoblot is shown.  The identities of the SR proteins are listed on the 
left side of the gel.  The “<” symbol indicates the dye front of the gel.  (C) Quantitation 
of the immunoblot data from n = 4 independent experiments.  The amounts of the 
phosphorylated SR proteins in each treatment were measured by densitometry and are 
indicated on each graph by arbitrary densitometric units (Arb. Dens. U.).  The “*” symbol 


















































































































































Figure 4 (continued) 
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